ads_id stringlengths 8 8 | arxiv_id int64 0 999 | title stringlengths 0 236 | abstract stringlengths 0 4.26k ⌀ | embed listlengths 1.54k 1.54k | date date32 | cites int64 1 1.16k | bibcode stringlengths 8 8 | keywords listlengths 0 30 | ads_keywords listlengths 0 14 | read_count int64 0 0 | doi stringlengths 13 16.8k ⌀ | authors listlengths 0 66 | aff listlengths 0 66 | cite_bibcodes listlengths 1 1.16k | ref_bibcodes listlengths 0 0 | umap_x float32 4.76 33.7 | umap_y float32 2.73 7.65 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39844819 | 0 | Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies. | In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual-target CAR-T therapies which can be designed to r... | [
0.021476397290825844,
-0.012967296876013279,
0.059178426861763,
0.059794869273900986,
-0.04632120952010155,
-0.00737528782337904,
-0.003563805017620325,
0.04000268131494522,
-0.00974198430776596,
0.004645330365747213,
-0.0049122716300189495,
-0.02718949317932129,
-0.029831387102603912,
0.0... | 2025-01-23 | 63 | 39844819 | [
"target combinations",
"target",
"superior antitumor CAR effects",
"various cancer types",
"antigen escape",
"tumor cells",
"varying degrees",
"tumor models",
"different types",
"tumor",
"different dual-target CAR-T studies",
"dual-target CAR-T therapies",
"various preclinical and clinical s... | [
"cancer immunotherapy",
"dual-target CAR-T",
"hematological malignancies",
"solid tumors"
] | 0 | 10.1155/jimr/5845167
10.1073/pnas.90.2.720
10.1038/s41591-019-0564-6
10.1182/blood.2019001641
10.1182/blood-2017-02-769208
10.1038/s41591-019-0549-5
10.1016/j.ajodo.2021.06.028
10.1172/JCI85309
10.1056/NEJMoa1709866
10.1182/bloodadvances.2020003092
10.3389/fimmu.2019.02664
10.1016/j.annonc.2020.10.478
10.1182/blood.202... | [
"Zhang",
"Liu"
] | [
"School of Medicine, University of Tsinghua, Beijing, China.\nDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.",
"Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."
] | [
"39844819",
"31650176",
"28408462",
"36127190",
"27111235",
"29385370",
"33147337",
"33098993",
"33156925",
"29385376",
"26516065",
"26907630",
"29812997",
"30896447",
"27412889",
"33626253",
"24048066",
"30135176",
"22526592",
"31725148",
"31697824",
"33833386",
"2951523... | [] | 8.246161 | 4.160666 |
39844295 | 1 | Application of adoptive cell therapy in malignant melanoma. | Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to metastasis and drug resistance. Thus, adoptive cell therapy (ACT), employin... | [
-0.0025810925289988518,
0.042373497039079666,
0.051993075758218765,
0.05337037518620491,
-0.00657445564866066,
0.0006899950094521046,
-0.004960432182997465,
0.029482828453183174,
0.007505209185183048,
-0.003752604592591524,
0.02045505680143833,
-0.051993075758218765,
-0.030429722741246223,
... | 2025-01-23 | 112 | 39844295 | [
"chimeric antigen receptor",
"adoptive cell therapy",
"skin pigment cells",
"immune cells",
"T cell",
"engineered T-cell receptor T cells",
"advanced melanoma",
"malignant melanoma",
"Cutaneous melanoma",
"tumor",
"surgical resection",
"future prospects",
"specific tumor-recognizing receptor... | [
"Adoptive Cell Therapy",
"Chimeric Antigen Receptors (CARs)-T cell",
"Malignant Melanoma",
"Natural Killer (NK) Cells",
"T-cell Receptors",
"Tumor-infiltrating Lymphocytes"
] | 0 | 10.1186/s12967-025-06093-2
10.3322/caac.21492
10.3322/caac.21332
10.3322/caac.21352
10.3390/ijms242115881
10.1016/j.critrevonc.2020.103208
10.1016/S0140-6736(21)01206-X
10.1080/21645515.2021.1971015
10.1016/j.clinthera.2015.02.018
10.1056/NEJMoa1504030
10.1056/NEJMoa1910836
10.1186/s13578-023-01073-9
10.1146/annurev-im... | [
"Hu",
"Xuan",
"Wang",
"Shen",
"Gao",
"Zhou",
"Wei",
"Gu"
] | [
"Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.",
"Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.",
"D... | [
"39844295",
"30207593",
"26742998",
"27232110",
"37958863",
"33383207",
"34509219",
"34882516",
"25823918",
"26027431",
"31562797",
"37386520",
"35471840",
"34441278",
"24670642",
"24853952",
"27232329",
"22439926",
"28187290",
"27951441",
"34743069",
"30470934",
"9619397... | [] | 10.290885 | 4.705851 |
39844281 | 2 | Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma. | Chimeric antigen receptor (CAR) T-cell therapy plays a critical role in the treatment of B-cell hematologic malignancies. The combination of PD-1 inhibitors and CAR-T has shown encouraging results in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, there are still cases w... | [
0.006582936272025108,
-0.010425412096083164,
0.025771990418434143,
0.05952047184109688,
0.010011427104473114,
-0.0325123593211174,
0.0029110105242580175,
0.017853809520602226,
-0.013947195373475552,
0.003810406429693103,
-0.00629722885787487,
0.011200903914868832,
-0.05317659676074982,
0.0... | 2025-01-23 | 20 | 39844281 | [
"IL4I1 levels",
"IL4I1",
"DLBCL patients",
"R/R DLBCL patients",
"DLBCL treatment",
"Pfeiffer cells",
"R/R DLBCL",
"tumor tissue",
"combination therapy",
"Correlation analysis",
"CD19 CAR-T",
"Kyn",
"CD19 CAR-T. Therefore",
"poor prognosis",
"CAR-T cells",
"potential mechanisms",
"pa... | [
"CD19 CAR-T",
"DLBCL",
"IL4I1",
"Metabolism",
"PD-1 inhibitor"
] | 0 | 10.1186/s12967-024-06028-3
10.1056/NEJMoa011795
10.1016/j.blre.2023.101140
10.1056/NEJMoa1804980
10.1158/2643-3230.BCD-23-0056
10.1182/bloodadvances.2020003844
10.1136/jitc-2020-001466
10.1182/blood-2016-09-738245
10.1016/j.cell.2018.09.007
10.1158/1078-0432.CCR-20-1457
10.1016/j.tranon.2021.101085
10.3389/fonc.2019.00... | [
"Zhang",
"Zhang",
"Xiao",
"Liu",
"Zhao"
] | [
"Department of Hematology, Tianjin First Central Hospital, Tianjin, China.",
"Department of Hematology, First Center Clinic College of Tianjin Medical University, Tianjin, China.",
"Boyalife wsn ltd, Shen Zhen, China.",
"Boyalife wsn ltd, Shen Zhen, China. liuqingxi66@aliyun.com.",
"Department of Hematology... | [
"39844281",
"11807147",
"30501490",
"33414262",
"28031179",
"30290143",
"33028589",
"31482064",
"36275688",
"32818467",
"26885856",
"26850336",
"35704993",
"36045296",
"34113569",
"26813675",
"30290143",
"36779699",
"33828302",
"32217098"
] | [] | 7.412257 | 5.586925 |
39843688 | 3 | Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms. | Treatment for neuroendocrine neoplasms (NENs) is tailored to the tumor's site of origin, grade, and differentiation. NENs are categorized into two main types: well-differentiated neuroendocrine tumors (NETs), which tend to grow more slowly and are less aggressive, and poorly differentiated neuroendocrine carcinomas (NE... | [
-0.005444354843348265,
-0.00921536237001419,
0.05976240336894989,
0.04035157337784767,
-0.002009510761126876,
0.02543487958610058,
0.029546532779932022,
0.03540324792265892,
0.003908460959792137,
0.024024486541748047,
0.01702033169567585,
-0.021442750468850136,
-0.00969346147030592,
0.0119... | 2025-01-23 | 60 | 39843688 | [
"cancer cells",
"small cell lung cancer",
"immune checkpoint inhibitors",
"new therapies",
"other cancers",
"chimeric antigen receptor T cells",
"receptor radionuclide therapy",
"bispecific T cell engagers",
"immune attack",
"NENs",
"cancer vaccines",
"new hope",
"other therapeutic agents",
... | [
"Gastroenteropancreatic neuroendocrine cancers",
"Immune checkpoint inhibitors",
"Immunotherapy",
"Neuroendocrine carcinoma",
"Neuroendocrine tumor"
] | 0 | 10.1007/s11864-024-01283-4
10.1007/s00428-006-0250-1
10.1007/s00428-007-0452-1
10.1093/annonc/mds276
10.1111/cas.12473
10.1111/jne.13249
10.1056/NEJMoa1809064
10.1016/S0140-6736(19)32222-6
10.7150/jca.13711
10.1002/cncr.32883
10.1530/ERC-20-0382
10.1158/1078-0432.CCR-19-3014
10.1158/1078-0432.CCR-19-3356
10.1002/cncr.3... | [
"Urman",
"Schonman",
"De Jesus-Acosta"
] | [
"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.",
"Johns Hopkins Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.",
"The Sidney Kimmel Comprehensive ... | [
"39843688",
"16967267",
"17674042",
"22967994",
"24975505",
"36924180",
"30280641",
"31590988",
"26958083",
"32320048",
"33480358",
"31980466",
"31969335",
"33882143",
"37221181",
"39117670",
"32532787",
"32203769",
"33428585",
"25991820",
"34568063",
"33409812",
"3598395... | [] | 11.116188 | 5.0375 |
39841845 | 4 | Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. | A major limiting factor in the success of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors is targeting tumor antigens also found on normal tissues. CAR T cells against GD2 induced rapid, fatal neurotoxicity because of CAR recognition of GD2 | [
0.03570399805903435,
0.02385634556412697,
0.057282835245132446,
0.07232820242643356,
-0.03846461698412895,
-0.04488305747509003,
0.012629829347133636,
0.004790823440998793,
-0.02995271049439907,
-0.005112895742058754,
-0.020934689790010452,
-0.011813146993517876,
-0.035934049636125565,
0.0... | 2025-01-22 | 1 | 39841845 | [
"CAR T cells",
"tumor antigens",
"T cell therapy",
"chimeric antigen receptor",
"solid tumors",
"CAR recognition",
"GD2",
"normal tissues",
"CAR",
"rapid, fatal neurotoxicity",
"A major limiting factor",
"the success",
"the treatment"
] | [] | 0 | 10.1126/sciadv.ads3403 | [
"Vogt",
"Silberman",
"Lin",
"Han",
"Laflin",
"Gellineau",
"Heller",
"Scheinberg"
] | [
"Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.\nGraduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.\nTri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.",
"Molecular... | [
"39841845"
] | [] | 9.616429 | 6.79694 |
39841806 | 5 | Triple knockdown of | Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the landscape of cancer treatment, in particular in the context of hematologic malignancies. However, for solid tumors that lack tumor-specific antigens, CAR-T cells can infiltrate and attack nonmalignant tissues expressing the CAR target antigen, lea... | [
0.013676300644874573,
0.025339338928461075,
0.047948043793439865,
0.07261629402637482,
-0.04267190769314766,
-0.04850342869758606,
-0.014960622414946556,
-0.00861421786248684,
-0.003343866905197501,
0.003502961015328765,
-0.005660854279994965,
-0.011269642040133476,
-0.04294959828257561,
-... | 2025-01-22 | 1 | 39841806 | [
"CAR)-T cell therapies",
"solid tumors",
"tumor",
"Chimeric antigen receptor",
"improved CAR-T cell therapy",
"target",
"CAR-T cells",
"cancer treatment",
"tumor-specific antigens",
"migration molecules",
"the CAR target antigen",
"CAR-T therapy",
"blocking antibodies",
"CAR",
"nonmalign... | [] | 0 | 10.1126/scitranslmed.adl6432 | [
"Wang",
"Wu",
"Cui",
"Bian",
"Zheng",
"Zhu",
"Geng",
"Sun",
"Pan",
"Shi",
"Yi",
"Song",
"Li",
"Shen",
"Li",
"Shen",
"Yan",
"Hao",
"Sun",
"Zhang",
"Zhang",
"Jin",
"Zhai"
] | [
"Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.\nShanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.",
"Department... | [
"39841806"
] | [] | 8.998252 | 5.280612 |
39840882 | 6 | [Patient with diffuse large B-cell lymphoma: a good example of network in care.]. | Chimeric Antigen Receptor T cell (CAR-T) therapy has revolutionized prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Success of CAR-T treatment heavily relies on early referral to the CAR-T center, on a short time of infusion of CAR-T cells from the lymphocyte collection and on a reduced burden of dise... | [
0.018854942172765732,
0.02260638028383255,
0.052886709570884705,
0.06867451965808868,
-0.024256035685539246,
0.012384630739688873,
-0.02891172654926777,
0.043184295296669006,
-0.01984473504126072,
0.004994788207113743,
0.006684156600385904,
-0.013698244467377663,
-0.054548583924770355,
-0.... | 2025-01-22 | 1 | 39840882 | [
"marginal zone lymphoma",
"holding therapy",
"early referral",
"complete remission",
"diffuse large B-cell lymphoma",
"patients",
"disease",
"BCL6 rearrangements",
"CAR-T cells",
"Chimeric Antigen Receptor T cell (CAR-T) therapy",
"CAR-T treatment",
"infusion",
"centers",
"High-grade B-cel... | [] | 0 | 10.1701/4416.44128 | [
"Tisi"
] | [
"UO Ematologia, Ospedale San Bortolo, Vicenza."
] | [
"39840882"
] | [] | 6.266233 | 5.473475 |
39839908 | 7 | A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency. | Chimeric antigen receptor (CAR)-T-cell therapy is a breakthrough in the field of cancer immunotherapy, wherein T cells are genetically modified to recognize and attack cancer cells. Delivery of the CAR gene is a critical step in this therapy and is usually achieved by transducing patient T cells with a lentiviral vecto... | [
-0.0014690025709569454,
-0.01320493035018444,
-0.009483763948082924,
0.024350037798285484,
-0.019641874358057976,
-0.029156289994716644,
-0.021763000637292862,
-0.019090136513113976,
0.017398139461874962,
-0.022400563582777977,
-0.007086768746376038,
0.00039617856964468956,
-0.04404095560312... | 2025-01-22 | 22 | 39839908 | [
"CAR LV",
"LV potency",
"LV MOA",
"LV quantification",
"T cells",
"activated T cells",
"patient T cells",
"LV",
"Jurkat reporter cells",
"Jurkat T cells",
"target cells",
"simple bioassays",
"quality control settings",
"potency testing",
"CAR",
"functional titer",
"potency",
"CAR e... | [
"CAR-T",
"bioassay",
"lentivirus",
"potency assay"
] | 0 | 10.1093/abt/tbae032
10.1016/j.ebiom.2020.102931
10.1038/nbt0102-70
10.4049/jimmunol.172.1.104
10.3390/biom12091303
10.3389/fmed.2023.1190016
10.1016/j.jcyt.2022.09.004
10.1186/1472-6750-6-34
10.1016/j.omtm.2024.101186
10.1038/nri1330
10.1016/j.jim.2016.01.007
10.1002/cti2.1216
10.1093/protein/gzz027
10.1016/j.omtm.2020... | [
"Gilden",
"Stecha",
"Hartnett",
"Cong"
] | [
"Research and Development, Promega Corp., Madison, WI 53711, United States.",
"Research and Development, Promega Corp., Madison, WI 53711, United States.",
"Research and Development, Promega Corp., Madison, WI 53711, United States.",
"Research and Development, Promega Corp., Madison, WI 53711, United States."... | [
"39839908",
"32739874",
"11753365",
"14688315",
"20683006",
"37215709",
"36253252",
"16836756",
"38282894",
"15057788",
"26780292",
"31504896",
"32083149",
"19427315",
"11948485",
"37559730",
"19561539",
"11983154",
"26830879",
"36513049",
"37803832",
"36809225"
] | [] | 8.165737 | 4.711771 |
39837618 | 8 | Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment. | In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved for patients with d... | [
-0.029780112206935883,
0.007054430432617664,
0.02348320372402668,
0.03451462835073471,
-0.008457031100988388,
-0.04793698340654373,
-0.0031869218219071627,
0.024666834622621536,
-0.028217721730470657,
0.03053763508796692,
0.03281020373106003,
-0.020701676607131958,
-0.03650312498211861,
-0... | 2025-01-22 | 61 | 39837618 | [
"TIL immunotherapy",
"TIL manufacturing",
"TIL",
"clinical practice guidelines",
"underlying clinical rationale",
"patients",
"required resources",
"cellular immunotherapy",
"durable tumor regression",
"T cells",
"sufficient tumor",
"effector T cell products",
"hospital inpatient resources",... | [
"Adoptive cell therapy - ACT",
"Cytokine",
"Immunotherapy",
"Surgery",
"Tumor infiltrating lymphocyte - TIL"
] | 0 | 10.1136/jitc-2024-010207
10.1126/science.aad1253
10.1172/JCI82416
10.1016/j.ccell.2023.11.005
10.1016/j.immuni.2023.09.011
10.1126/science.3489291
10.1056/NEJM198812223192527
10.1126/science.1076514
10.1158/1078-0432.CCR-21-1171
10.1093/annonc/mdz398
10.1056/NEJMoa2210233
10.1136/jitc-2023-008372
10.1136/jitc-2022-0057... | [
"Turcotte",
"Donia",
"Gastman",
"Besser",
"Brown",
"Coukos",
"Creelan",
"Mullinax",
"Sondak",
"Yang",
"Rohaan",
"Marie Svane",
"Lotze",
"Haanen",
"Goff"
] | [
"Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.",
"Department of Oncology, National Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Denmark.",
"Iovance Biotherapeutics, Philadelphia, Pennsylvania, USA.",
"Davidoff Center & Samueli Institute, Rabin Medical C... | [
"39837618",
"26516200",
"26389673",
"38039963",
"37820582",
"3489291",
"3264384",
"12242449",
"34413159",
"31566658",
"36477031",
"38531663",
"36600653",
"38423748",
"34385708",
"30518633",
"34607899",
"38309721",
"28198830",
"31164343",
"35104158",
"24812403",
"29867227"... | [] | 10.194453 | 4.454338 |
39836430 | 9 | Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma. | Orvacabtagene autoleucel (orva-cel; JCARH125), a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), was evaluated in relapsed/refractory multiple myeloma (RRMM) patients in the EVOLVE phase 1/2 study (NCT03430011). We applied a modified piecewise model to characterize orva-cel transgene kinetics and assesse... | [
0.03012278489768505,
0.003520004218444228,
0.03740132227540016,
0.01596098765730858,
-0.0707135796546936,
-0.016887841746211052,
-0.00018017446564044803,
-0.004307149443775415,
0.0290868878364563,
-0.012062744237482548,
0.00372104998677969,
-0.027914689853787422,
-0.043153274804353714,
0.0... | 2025-01-21 | 1 | 39836430 | [
"CAR+ T cells",
"T cell biology",
"Traditional piecewise models",
"plasma cells",
"traditional models",
"dose levels",
"baseline disease burden",
"encompassed baseline demographics",
"various covariates",
"dose level",
"a cell number-dependent expansion phase",
"maximum orva-cel transgene leve... | [] | 0 | 10.1158/1078-0432.CCR-24-2753 | [
"Hu",
"Li",
"Piasecki",
"Hosseyni",
"Yan",
"Liu",
"Ogasawara",
"Zhou",
"Cheng"
] | [
"Bristol-Myers Squibb (United States), Princeton, New Jersey, United States.",
"Bristol-Myers Squibb (United States), Princeton, NJ, United States.",
"Bristol-Myers Squibb (United States), United States.",
"Bristol-Myers Squibb (United States), Boudry, Switzerland.",
"Bristol-Myers Squibb (United States), U... | [
"39836430"
] | [] | 5.44703 | 5.483919 |
39835140 | 10 | Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. | Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successes to solid tumors remains limited due to several intrinsic challenges, including... | [
0.030550353229045868,
0.0016721346182748675,
0.04794958978891373,
0.05689777061343193,
-0.0392499715089798,
-0.037238892167806625,
-0.006163171958178282,
0.019082672894001007,
0.007445518393069506,
0.012292449362576008,
-0.004392178263515234,
-0.01094796322286129,
-0.04826594144105911,
0.0... | 2025-01-21 | 74 | 39835140 | [
"CAR T therapies",
"CAR T cell therapy",
"T cell therapy",
"immunosuppressive tumor microenvironments",
"antigen identification",
"tumor infiltration",
"solid tumors",
"Chimeric antigen receptor",
"antigen heterogeneity",
"CAR",
"CARs",
"remarkable clinical success",
"several intrinsic chall... | [
"CAR T cell",
"cancer",
"immunotherapy",
"solid tumors",
"structure",
"targets"
] | 0 | 10.3389/fimmu.2024.1489827
10.1158/2159-8290.CD-12-0548
10.1159/000496870
10.3390/ijms21020515
10.1056/NEJMoa1709866
10.1016/S1470-2045(18)30864-7
10.1056/NEJMoa1914347
10.1016/S0140-6736(20)31366-0
10.1056/NEJMoa2024850
10.1016/S0140-6736(21)00933-8
10.1038/s41591-022-02182-7
10.1182/blood.V96.5.1999
10.1158/1078-0432... | [
"Khan",
"Choi",
"Veena",
"Lee",
"Shin"
] | [
"Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, CA, United States.\nDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA, United States.",
... | [
"39835140",
"31947597",
"30518502",
"10961908",
"28652918",
"37192158",
"35202772",
"31672285",
"32029687",
"34737753",
"35483375",
"33408186",
"36084652",
"30753824",
"27059623",
"32385241",
"37963244",
"31064990",
"25675873",
"33746981",
"30482221",
"39013470",
"2332266... | [] | 8.945672 | 4.319164 |
39833408 | 11 | Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. | Long-term risks of gene therapy are not fully understood. In this study, we evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T cell therapy trials. The trials employed integrating gammaretroviral or lentiviral vectors to deliver engineered receptors to target HIV... | [
-0.00005343982047634199,
0.025706466287374496,
0.07187555730342865,
0.019798407331109047,
-0.0575190931558609,
-0.01465944480150938,
0.046145785599946976,
0.010714911855757236,
0.016174331307411194,
0.012049177661538124,
-0.0057390909641981125,
-0.039293836802244186,
-0.02041601575911045,
... | 2025-01-21 | 78 | 39833408 | [
"engineered T cell therapies",
"malignant T cells",
"vector integration sites",
"vector integration",
"vector copy number",
"tumor suppressor genes",
"gene therapy",
"secondary malignancies",
"specific genes",
"engineered receptors",
"incident tumor samples",
"safety outcomes",
"38 T cell th... | [] | 0 | 10.1038/s41591-024-03478-6
10.1056/NEJMra1706910
10.1056/NEJMra1706169
10.1016/j.ymthe.2023.11.001
10.1172/JCI35700
10.1056/NEJM200301163480314
10.1126/science.1088547
10.1172/JCI35798
10.1038/nm.2088
10.1016/j.omtm.2018.08.006
10.1016/j.ymthe.2017.09.008
10.1016/j.ymthe.2017.10.012
10.1016/j.ymthe.2020.01.001
10.1016/... | [
"Jadlowsky",
"Hexner",
"Marshall",
"Grupp",
"Frey",
"Riley",
"Veloso",
"McConville",
"Rogal",
"Czuczman",
"Hwang",
"Li",
"Leskowitz",
"Farrelly",
"Karar",
"Christensen",
"Barber-Rotenberg",
"Gaymon",
"Aronson",
"Bernstein",
"Melenhorst",
"Roche",
"Everett",
"Zolnoski",
... | [
"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.",
"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.\nDepartment of Medicine, Division of Hematology/Oncology, Perelman School of... | [
"39833408",
"31365802",
"29972754",
"37927037",
"18688285",
"12529469",
"14564000",
"18688286",
"20098431",
"30211249",
"28970045",
"29203150",
"31968213",
"12202041",
"17507662",
"19259065",
"1373087",
"18024124",
"8174106",
"34644108",
"29849141",
"31387880",
"38265704"... | [] | 6.571954 | 4.618594 |
39832905 | 12 | CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist? | CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, this therapy brings a new approach in resetting immune dysregulation and ... | [
0.019357407465577126,
0.013966148719191551,
0.06678654253482819,
0.050659243017435074,
0.01608082465827465,
-0.01273452490568161,
-0.017033590003848076,
0.018381403759121895,
0.010242230258882046,
0.018183879554271698,
-0.01915988326072693,
-0.02944277971982956,
-0.05144933983683586,
0.010... | 2025-01-21 | 29 | 39832905 | [
"optimal patient selection",
"CD19 CAR T-cell therapy",
"patients",
"resetting immune dysregulation",
"haematology",
"toxicities",
"toxicity",
"systemic sclerosis",
"valuable insights",
"haematological malignancies",
"Recent reports",
"autoimmune diseases",
"clinical practice",
"CD19-direc... | [
"Autoimmune Diseases",
"Hematology",
"Lupus Erythematosus, Systemic"
] | 0 | 10.1136/lupus-2024-001157
10.1016/S1470-2045(21)00375-2
10.1016/S1470-2045(18)30864-7
10.1016/S0140-6736(20)31366-0
10.1200/JCO.19.02104
10.1182/blood-2021-148078
10.1056/NEJMoa1709866
10.1200/JCO.22.00642
10.1016/S0140-6736(21)01222-8
10.1038/s41591-021-01622-0
10.1056/NEJMoa1914347
10.1038/s41591-022-02017-5
10.1056/... | [
"Kuipers",
"Kersten"
] | [
"Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands ilse.kuipers@amsterdamumc.nl.",
"Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands.\nCancer Center Amsterdam, Amsterdam, The Netherlands.\nLYMMCARE Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands."
] | [
"39832905",
"34516954",
"30518502",
"32888407",
"32401634",
"29385370",
"36399695",
"34097852",
"34921238",
"32242358",
"36109639",
"38381673",
"34175021",
"33626253",
"36138152",
"35757715",
"34923107",
"37951502",
"34002066",
"30592986",
"36989488",
"36877916",
"3459030... | [] | 7.389462 | 4.504431 |
39832454 | 13 | CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. | Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulated B cell activation, autoantibody production, and nephritis. B cell activating factor (BAFF) overexpression enhances autoreactive B-cell survival, driving autoimmunity. BAFF specific belimumab and CD20 specific rituximab antibodies ... | [
-0.0008029377204366028,
-0.02016991190612316,
0.04874201864004135,
0.05514811351895332,
-0.03848298266530037,
0.005730088334530592,
-0.019229887053370476,
0.012672925367951393,
-0.017825651913881302,
-0.0033887308090925217,
-0.030800314620137215,
-0.0071198162622749805,
-0.03892398253083229,... | 2025-01-21 | 1 | 39832454 | [
"B cells",
"mature B cells",
"dysregulated B cell activation",
"B cell activating factor",
"alternative B cell depletion therapies",
"plasma cells",
"peripheral blood mononuclear cells",
"SLE therapy",
"SLE patients",
"SLE",
"autoreactive B-cell survival",
"BAFF specific belimumab",
"BAFF CA... | [
"Autoimmune",
"BAFF",
"CAR-T cells",
"Cytotoxicity",
"SLE"
] | 0 | 10.1016/j.jaut.2025.103369 | [
"Uppin",
"Gibbons",
"Troje",
"Feinberg",
"Webber",
"Moriarity",
"Parameswaran"
] | [
"Division of Haematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.",
"Luminary Therapeutics, Minneapolis, MN, USA.",
"Luminary Therapeutics, Minneapolis, MN, USA.",
"Division of Haematology/Oncology, Department of Medicine, Case Western Reserve University, Clevelan... | [
"39832454"
] | [] | 6.800169 | 5.149509 |
39831708 | 14 | Generation of Human Chimeric Antigen Receptor Regulatory T Cells. | Chimeric antigen receptor (CAR) T-cell therapy has reshaped the face of cancer treatment, leading to record remission rates in previously incurable hematological cancers. These successes have spurred interest in adapting the CAR platform to a small yet pivotal subset of CD4 | [
0.03502711281180382,
-0.004577272105962038,
0.047708116471767426,
0.07299888134002686,
-0.03495587408542633,
-0.03322232887148857,
-0.010454703122377396,
0.03711686655879021,
0.00656609982252121,
0.003090103855356574,
-0.006815445143729448,
-0.019401459023356438,
-0.030752619728446007,
0.0... | 2025-01-20 | 1 | 39831708 | [
"cancer treatment",
"remission rates",
"Chimeric antigen receptor",
"CAR",
"interest",
"previously incurable hematological cancers",
"CD4",
"CAR) T-cell therapy",
"the CAR platform",
"a small yet pivotal subset",
"the face",
"These successes"
] | [] | 0 | 10.3791/67200 | [
"Cochrane",
"Robino",
"Ferreira"
] | [
"Department of Microbiology and Immunology, Medical University of South Carolina; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina; Hollings Cancer Center, Medical University of South Carolina.",
"Department of Microbiology and Immunology, Medical University of South Caro... | [
"39831708"
] | [] | 8.089559 | 4.375112 |
39825416 | 15 | Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults. | Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging therapy is used to control disease prior to start of lymphodepletion before CAR infusion and thereby improve efficac... | [
0.007020209450274706,
0.020689120516180992,
0.06338685005903244,
0.06635890901088715,
-0.005636664107441902,
0.013169297948479652,
0.0032891216687858105,
-0.0017230258090421557,
0.014514410868287086,
0.017191825434565544,
-0.03438365086913109,
-0.028413912281394005,
-0.041275754570961,
0.0... | 2025-01-18 | 9 | 39825416 | [
"Bridging therapy",
"CAR therapy",
"different bridging strategies",
"bridging regimens",
"high-intensity bridging therapy",
"Anti-CD19 chimeric antigen receptor T cells",
"Patients",
"patients",
"no systemic bridging therapy",
"CAR infusion",
"bacterial adverse events",
"more adverse events",
... | [
"B-ALL",
"Bridging therapy",
"CAR T cells"
] | 0 | 10.1186/s13045-024-01659-x | [
"Breidenbach",
"Bader",
"Attarbaschi",
"Rossig",
"Meisel",
"Metzler",
"Subklewe",
"Mueller",
"Schlegel",
"Teichert von Lüttichau",
"Bourquin",
"Escherich",
"Cario",
"Lang",
"Coffey",
"von Stackelberg",
"Willier",
"Strahm",
"Peters",
"Feuchtinger"
] | [
"Bavarian Cancer Research Center (BZKF), R/R ALL Study Group, Bavaria, Germany.\nDepartment of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Dr. Von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.",
"Department of Pediatrics, Division for Stem Cell Tra... | [
"39825416",
"29385370",
"36607834",
"34882493",
"29385376",
"25317870",
"28924019",
"31650176",
"38356450"
] | [] | 6.480481 | 5.460928 |
39824562 | 16 | Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research. | Treatment with autologous chimeric antigen receptor (CAR)-modified T cells can achieve outstanding clinical response rates in heavily pretreated patients with B and plasma cell malignancies. However, relapses occur, and they limit the efficacy of this promising treatment approach. The complex GMP-compliant production a... | [
0.008551987819373608,
0.014783762395381927,
0.057580143213272095,
0.02990766055881977,
-0.036248765885829926,
-0.03809521719813347,
0.022886283695697784,
0.01684887334704399,
0.0037414943799376488,
-0.015779875218868256,
-0.00008247156074503437,
-0.014455773867666721,
-0.021914467215538025,
... | 2025-01-18 | 1 | 39824562 | [
"CAR T cells",
"CAR T cell production",
"CAR T cell therapy",
"CAR)-modified T cells",
"cancer cells",
"human CAR-modified T cells",
"the administered CAR T cells",
"high treatment costs",
"experimental immunotherapeutic treatment",
"proven clinical success",
"outstanding clinical response rates... | [
"Adoptive T cell therapy",
"CAR T cells",
"Chimeric antigen receptor",
"Immunotherapy",
"Retrovirus"
] | 0 | 10.1016/bs.mcb.2024.10.017 | [
"Stock",
"Fertig",
"Menkhoff",
"Strzalkowski",
"Caruso",
"Kobold"
] | [
"Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, A Partnership Between the DKFZ Heidelberg and LMU University Ho... | [
"39824562"
] | [] | 8.767393 | 3.024045 |
39824530 | 17 | Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors. | Glucose deprivation inhibits T-cell metabolism and function. Glucose levels are low in the tumor microenvironment of solid tumors and insufficient glucose uptake limits the antitumor response of T cells. Furthermore, glucose restriction can contribute to the failure of chimeric antigen receptor T (CAR-T) cell therapy f... | [
-0.017342347651720047,
0.025132853537797928,
0.029197467491030693,
0.024184444919228554,
-0.016924595460295677,
-0.03845575079321861,
0.018482696264982224,
0.039200928062200546,
-0.00261800573207438,
-0.009873621165752411,
-0.024613486602902412,
-0.0014593087835237384,
-0.008789724670350552,... | 2025-01-18 | 47 | 39824530 | [
"T cells",
"cell therapy",
"glucose restriction",
"low glucose uptake levels",
"insufficient glucose",
"glucose",
"Glucose deprivation",
"CAR-T cell function",
"CAR-T cell therapy",
"CAR-T cell activation",
"CAR-T cells",
"T-cell metabolism",
"T",
"Glucose restriction",
"Glucose transpor... | [
"Chimeric antigen receptor - CAR",
"Mitochondria",
"Nutrition",
"Solid tumor"
] | 0 | 10.1136/jitc-2024-010540
10.1056/NEJMra1706169
10.1038/s41573-021-00189-2
10.1126/sciimmunol.abq3016
10.3389/fimmu.2015.00001
10.1016/j.cmet.2017.06.016
10.1016/j.it.2012.01.010
10.1126/science.abb2683
10.1016/j.cell.2015.08.012
10.1182/blood-2007-06-096297
10.1016/j.cell.2015.08.016
10.1038/s41586-021-03442-1
10.1016/... | [
"Hu",
"Li",
"Liang",
"Liu",
"Wang",
"Shen",
"Zhao",
"Wang",
"Zhang"
] | [
"Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.",
"Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China yizhang@zzu.edu.cn fcclif1@zzu.edu.cn.\nZhongyuan Cel... | [
"39824530",
"29972754",
"33972771",
"37058548",
"25657648",
"28683298",
"22342741",
"33479154",
"26321681",
"18042802",
"26321679",
"26885860",
"32015548",
"31783892",
"29288199",
"34746799",
"17373964",
"24930970",
"18660845",
"28614802",
"32019781",
"35123658",
"2580963... | [] | 10.191236 | 4.997798 |
39820712 | 18 | PRDM1 is a key regulator of the natural killer T-cell central memory program and effector function. | Natural killer T cells (NKTs) are a promising platform for cancer immunotherapy, but few genes involved in regulation of NKT therapeutic activity have been identified. To find regulators of NKT functional fitness, we developed a CRISPR/Cas9-based mutagenesis screen that employs a guide RNA (gRNA) library targeting 1,11... | [
-0.0194774828851223,
0.04680023342370987,
0.041002631187438965,
0.03552574664354324,
-0.018120596185326576,
-0.0024855686351656914,
0.006913951598107815,
0.04129868000745773,
-0.020279278978705406,
0.006722753867506981,
0.006852274760603905,
0.003151676384732127,
-0.014568022452294827,
0.0... | 2025-01-17 | 1 | 39820712 | [
"NKT memory differentiation",
"GD2.CAR NKTs",
"central memory differentiation",
"NKT therapeutic activity",
"NKT functional fitness",
"PRDM1 knockout",
"targeted PRDM1 knockout",
"CAR NKTs",
"vivo antitumor activity",
"NKTs",
"PRDM1",
"NKT",
"Natural killer T cells",
"gRNA abundance",
"e... | [] | 0 | 10.1158/2326-6066.CIR-24-0259 | [
"Tian",
"Barragán",
"Yu",
"Martinez-Amador",
"Adaikkalavan",
"Rios",
"Guo",
"Drabek",
"Pardias",
"Xu",
"Montalbano",
"Zhang",
"Li",
"Courtney",
"Di Pierro",
"Metelitsa"
] | [
"Baylor College of Medicine, Houston, TX, United States.",
"Baylor College of Medicine, Houston, TX, United States.",
"Baylor College of Medicine, Houston, TX, United States.",
"Baylor College of Medicine, Houston, TX, United States.",
"Baylor College of Medicine, Houston, TX, United States.",
"Baylor Col... | [
"39820712"
] | [] | 11.209931 | 5.928877 |
39820375 | 19 | The emergence of bispecific T-cell engagers in the treatment of follicular and large B-cell lymphomas. | The rapid emergence of CD20-targeting T-cell engagers in follicular lymphoma and large B-cell lymphoma has further expanded the treatment options for patients with relapsed or refractory disease. Herein, we review and discuss the standard-of-care products and indications for mosunetuzumab, epcoritamab, and glofitamab. ... | [
0.019870135933160782,
0.010344400070607662,
0.04219626262784004,
0.02797490544617176,
-0.029612233862280846,
0.02577620930969715,
0.0035261011216789484,
0.05744679644703865,
0.017601268365979195,
-0.02045489475131035,
0.009853201918303967,
-0.027694221585989,
-0.04579838365316391,
0.009075... | 2025-01-17 | 1 | 39820375 | [
"likely future indications",
"ongoing trials",
"follicular lymphoma",
"T-cell engagers",
"antigen receptor T-cell therapy",
"immune effector cell-related toxicities",
"particular emphasis",
"large B-cell lymphoma",
"indications",
"CD20-targeting T-cell engagers",
"care",
"patients",
"the reg... | [] | 0 | null | [
"Lutfi",
"Ahmed",
"Hoffmann",
"Tun",
"McGuirk"
] | [
"Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.",
"Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas.",
"Division of Hematologic Malignancies and Cellular Therapeutic... | [
"39820375"
] | [] | 5.959595 | 6.407292 |
39820359 | 20 | Phase I study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult B-ALL patients. | CD19-directed chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy elicits high response rates but fails to induce durable responses in most adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In a previous clinical trial (NCT01865617), we observed anti-CAR immune responses a... | [
0.005445249378681183,
0.03553156554698944,
0.04558813199400902,
0.03627283498644829,
-0.024387797340750694,
-0.03318420797586441,
-0.009692111052572727,
0.011829441413283348,
0.011934454552829266,
-0.00003329926039441489,
-0.01624617725610733,
-0.029675526544451714,
-0.04899797588586807,
0... | 2025-01-17 | 1 | 39820359 | [
"high response rates",
"durable responses",
"extramedullary responses",
"anti-CAR immune responses",
"high marrow burden",
"low marrow disease burden",
"marrow disease",
"CD19 CAR T-cells",
"Durable remissions",
"patients",
"vivo CAR T-cell expansion",
"most adults",
"prolong remissions",
... | [] | 0 | 10.1182/bloodadvances.2024015314 | [
"Gauthier",
"Liang",
"Huang",
"Kimble",
"Hirayama",
"Fiorenza",
"Voutsinas",
"Wu",
"Jaeger-Ruckstuhl",
"Pender",
"Kirchmeier",
"Torkelson",
"Braathen",
"Basom",
"Shadman",
"Kopmar",
"Cassaday",
"Riddell",
"Maloney",
"Turtle"
] | [
"University of Washington, United States.",
"Fred Hutchinson Cancer Center, United States.",
"Fred Hutchinson Cancer Center, Seattle, Washington, United States.",
"University of Washington, United States.",
"University of Washington, United States.",
"University of Sydney, Camperdown, Australia.",
"Fred... | [
"39820359"
] | [] | 6.589711 | 5.630523 |
39818472 | 21 | Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma. | Multiple myeloma (MM) remains incurable and patients eventually face the relapse/refractory dilemma. B cell maturation antigen (BCMA)-targeted immunotherapeutic approaches have shown great effectiveness in patients with relapsed/refractory MM, mainly including chimeric antigen receptor T cells (CAR-T), bispecific T cel... | [
0.02563696727156639,
0.03418262302875519,
0.09152283519506454,
0.04216192290186882,
-0.06463988870382309,
0.002531288657337427,
-0.0003626240068115294,
-0.002380260732024908,
-0.015442591160535812,
-0.009168645367026329,
0.013403715565800667,
-0.029173534363508224,
-0.022024884819984436,
0... | 2025-01-17 | 1 | 39818472 | [
"chimeric antigen receptor T cells",
"B cell maturation antigen",
"T cell engagers",
"resistance",
"BCMA)-targeted immunotherapeutic approaches",
"BCMA",
"great effectiveness",
"patients",
"MM",
"potential strategies",
"BCMA-targeted therapies",
"Multiple myeloma",
"BCMA-targeted immunothera... | [
"Antibody-drug conjugates",
"B cell maturation antigen",
"Bispecific T cell engagers",
"Chimeric antigen receptor T cells",
"Multiple myeloma",
"Resistance mechanism"
] | 0 | 10.1016/j.blre.2025.101256 | [
"Yue",
"Sun",
"Dai",
"Jin"
] | [
"Department of Hematology, First Hospital of Jilin University, Changchun, Jilin, China; Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, Changchun, Jilin, China.",
"Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address:... | [
"39818472"
] | [] | 4.816514 | 6.246012 |
39818091 | 22 | PD1-TLR10 fusion protein enhances the antitumor efficacy of CAR-T cells in colon cancer. | The immunosuppressive microenvironment negatively affects the efficacy of chimeric antigen receptor T (CAR-T) cells in solid tumors. Fusion protein that combining extracellular domain of inhibitory checkpoint protein and the cytoplasmic domain of stimulatory molecule may improve the efficacy of CAR-T cells by reversing... | [
0.04859326034784317,
-0.026751771569252014,
0.04210798442363739,
0.07884245365858078,
-0.011881955899298191,
0.00598151097074151,
0.00458022765815258,
0.02985543943941593,
0.014128641225397587,
0.001595262554474175,
-0.0014374734601005912,
-0.03687343746423721,
-0.052669722586870193,
-0.02... | 2025-01-17 | 1 | 39818091 | [
"Fusion protein",
"fusion protein",
"TLR10 transmembrane domain",
"PD1 extracellular domain",
"TLR10 intracellular domain",
"fusion protein armored CAR-T cells",
"inhibitory checkpoint protein",
"second generation anti-CEA CAR",
"extracellular domain",
"better anti-tumor activity",
"transmembran... | [
"CAR-T",
"Fusion protein",
"Immune checkpoint",
"TLR10"
] | 0 | 10.1016/j.intimp.2025.114083 | [
"Peng",
"Huang",
"Wu",
"Wu",
"Lu",
"Zhang",
"Liu"
] | [
"Department of Bioengineering, School of Life Sciences, Fudan University, Songhu Road 2005, 200438 Shanghai, China; TriArm Therapeutics, Niudun Road 200, 201203 Shanghai, China.",
"TriArm Therapeutics, Niudun Road 200, 201203 Shanghai, China.",
"TriArm Therapeutics, Niudun Road 200, 201203 Shanghai, China.",
... | [
"39818091"
] | [] | 9.321208 | 5.794305 |
39816133 | 23 | La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy. | The approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of hematological cancers has marked a new era in cancer care, with seven products being FDA approved since 2017. However, challenges remain, and while profound effects are observed initially in myeloma, the majority of patients relapse, ... | [
0.025006605312228203,
-0.0020679000299423933,
0.06670026481151581,
0.059987083077430725,
-0.029609929770231247,
-0.036203235387802124,
0.02113453671336174,
0.0284830741584301,
0.02658899873495102,
-0.006521377246826887,
0.009476376697421074,
-0.045457836240530014,
-0.07264622300863266,
0.0... | 2025-01-16 | 21 | 39816133 | [
"CAR T cell therapy",
"poor CAR T cell persistence",
"human CAR T cells",
"Guerrero et al",
"cancer care",
"tumor antigen heterogeneity",
"immune evasion mechanisms",
"hematological cancers",
"poor infiltration",
"profound effects",
"chimeric antigen receptor",
"patients relapse",
"CAR",
"... | [
"Glut1",
"cancer",
"chimeric antigen receptor T cells",
"cytokines",
"glucose",
"glycolysis",
"metabolism",
"tumor"
] | 0 | 10.1097/IN9.0000000000000055
10.1038/s41423-024-01148-8
10.3389/fimmu.2023.1121565
10.1038/s41467-024-52666-y
10.1126/sciadv.adj1431
10.1016/j.ymthe.2024.05.006
10.20900/immunometab20200029
10.1038/s42003-024-06164-y
10.1136/jitc-2023-008434
10.1038/s41586-024-07962-4
10.4110/in.2020.20.e6
10.1016/j.cell.2015.08.016
10... | [
"Slattery",
"Finlay",
"Darcy"
] | [
"School of Medicine, Trinity Translational Medicine Institute, St. James's Hospital, Dublin, Ireland.",
"School of Biochemistry and Immunology, Trinity Biomedical Sciences, Trinity College Dublin, Dublin, Ireland.\nSchool of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences, Trinity College Dublin... | [
"39816133",
"38565887",
"36999013",
"39370422",
"31747582",
"38809979",
"38720457",
"32879737",
"38627603",
"38964783",
"39322665",
"32158594",
"26321679",
"38787918",
"33828302",
"28614802",
"32591905",
"36890792",
"38600376",
"38600391",
"31076448"
] | [] | 8.369929 | 4.094183 |
39815137 | 24 | Optimal chemokine receptors for enhancing immune cell trafficking in adoptive cell therapy. | Recently, a strategy involving the engineering of chemokine receptors on immune cells was developed to optimize adoptive cell therapy (ACT) for solid tumors. Given the variability in chemokine secretion among different tumor types, identifying and modulating the appropriate chemokine receptors is crucial. In this study... | [
0.021250274032354355,
-0.0017371495487168431,
0.024123890325427055,
0.04518098011612892,
-0.011651428416371346,
-0.012237018905580044,
0.012943348847329617,
0.029846975579857826,
-0.018557768315076828,
-0.03211688995361328,
-0.011283171363174915,
-0.028567129746079445,
-0.01929428242146969,
... | 2025-01-16 | 37 | 39815137 | [
"chemokine receptors",
"tumor tissues",
"T cells",
"chemokine secretion",
"adoptive cell therapy",
"increased chemokine levels",
"immune cells",
"cell trafficking",
"cell migration",
"cell viability",
"different tumor types",
"solid tumors",
"normal tissues",
"chimeric antigen receptor-T c... | [
"Adoptive cell therapy",
"Chemokine",
"Chemokine receptor",
"Immune cell trafficking"
] | 0 | 10.1007/s12026-024-09560-y
10.1186/s13045-023-01492-8
10.1007/s00428-018-2484-0
10.1038/s41419-017-0238-6
10.1038/nm.4015
10.1158/1078-0432.CCR-06-1183
10.1158/2159-8290.CD-19-0790
10.1016/j.xcrm.2022.100543
10.1084/jem.187.4.655
10.1038/35876
10.1038/s41467-019-11869-4
10.3389/fimmu.2021.628906
10.1038/s41551-021-0073... | [
"Han",
"Jeong",
"Hong",
"Seo",
"Lee",
"Kim",
"Hong",
"Lee",
"Cha",
"Kim",
"Park",
"Gong",
"Lee"
] | [
"Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro, 43-Gil, Songpa-Gu, Seoul, 05505, Korea.\nBiomedical Sciences, Asan Medical Institute of Convergence Science and Technology, University of Ulsan College of Medicine, Seoul, South Korea.",
"Department of Pathology... | [
"39815137",
"37596653",
"30470934",
"29415996",
"26735408",
"17062687",
"31974169",
"35492880",
"9463416",
"9486651",
"31488817",
"33777013",
"34083764",
"23550147",
"33494834",
"37626090",
"29770138",
"21282551",
"29371915",
"32529292",
"35572194",
"35032108",
"33462245"... | [] | 9.815993 | 5.05102 |
39815015 | 25 | Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. | Allogeneic chimeric antigen receptor (CAR) T cells targeting disialoganglioside-GD2 (ALLO_GD2-CART01) could be a therapeutic option for patients with relapsed or refractory, high-risk neuroblastoma (r/r HR-NB) whose tumors did not respond to autologous GD2-CART01 or who have profound lymphopenia. We present a case seri... | [
0.007427464704960585,
0.023259535431861877,
0.05045161023736,
0.05841260403394699,
-0.029254259541630745,
-0.04635121673345566,
-0.030836867168545723,
0.03476940840482712,
0.002277995692566037,
-0.021353211253881454,
0.004211294464766979,
-0.025489572435617447,
-0.032203663140535355,
0.008... | 2025-01-16 | 35 | 39815015 | [
"autologous CAR T cells",
"T cell proliferation",
"T cell activation",
"cell polarization",
"humoral immune response",
"allogeneic hematopoietic stem cell transplantation",
"cell chemotaxis",
"transcriptomic signaling analysis",
"response",
"patients",
"Allogeneic chimeric antigen receptor",
"... | [] | 0 | 10.1038/s41591-024-03449-x
10.1016/S1470-2045(18)30578-3
10.1016/j.pcl.2014.09.015
10.1002/cncr.30934
10.1056/NEJMoa2210859
10.1136/jitc-2020-002328
10.1182/blood-2014-05-552729
10.1016/j.annonc.2021.12.003
10.1016/j.bbmt.2015.09.001
10.3389/fimmu.2018.00184
10.4049/jimmunol.2300083
10.1128/MCB.01288-12
10.1016/j.celre... | [
"Quintarelli",
"Del Bufalo",
"De Ioris",
"Guercio",
"Algeri",
"Pagliara",
"Silvestris",
"Di Nardo",
"Sinibaldi",
"Di Cecca",
"Iaffaldano",
"Manni",
"Fustaino",
"Garganese",
"Colafati",
"Bertaina",
"Becilli",
"Mastronuzzi",
"Fabozzi",
"Gunetti",
"Iacovelli",
"Bugianesi",
"... | [
"Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.\nDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.",
"Department of Hematology/Oncology, ... | [
"39815015",
"30442501",
"25435121",
"28885700",
"37018492",
"34006631",
"24876563",
"34923107",
"26386318",
"29467767",
"37449888",
"23275443",
"28930685",
"30952800",
"22421968",
"31521051",
"24856931",
"38774881",
"24081484",
"19437016",
"12815485",
"25156335",
"2341943... | [] | 9.686148 | 6.968077 |
39814734 | 26 | Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. | We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we develop clinically relevant fully immunocompetent syngeneic models to evaluate the potential for CAR-M to remodel the tumor microenv... | [
0.04202692210674286,
0.003244013525545597,
0.004124618135392666,
0.0646381825208664,
-0.07049677520990372,
0.003737273160368204,
0.016934234648942947,
0.03822610154747963,
0.023894337937235832,
-0.011668764986097813,
-0.00522613013163209,
-0.014791733585298061,
-0.033045362681150436,
-0.00... | 2025-01-16 | 63 | 39814734 | [
"anti-HER2 CAR",
"T cell anti-tumor immunity",
"non-responsive tumors",
"macrophage anti-tumor function",
"tumor control",
"tumor growth control",
"solid tumors",
"pre-clinical models",
"intratumoral T cell",
"tumor burden",
"M",
"long-term anti-tumor immunity",
"immunodeficient xenograft mo... | [] | 0 | 10.1038/s41467-024-55770-1 | [
"Pierini",
"Gabbasov",
"Oliveira-Nunes",
"Qureshi",
"Worth",
"Huang",
"Nagar",
"Griffin",
"Lian",
"Yashiro-Ohtani",
"Ross",
"Sloas",
"Ball",
"Schott",
"Sonawane",
"Cornell",
"Blumenthal",
"Chhum",
"Minutolo",
"Ciccaglione",
"Shaw",
"Zentner",
"Levitsky",
"Shestova",
"... | [
"Carisma Therapeutics Inc, Philadelphia, PA, USA.",
"Carisma Therapeutics Inc, Philadelphia, PA, USA.",
"Carisma Therapeutics Inc, Philadelphia, PA, USA.",
"Carisma Therapeutics Inc, Philadelphia, PA, USA.",
"Carisma Therapeutics Inc, Philadelphia, PA, USA.",
"Carisma Therapeutics Inc, Philadelphia, PA, U... | [
"39814734",
"29567707",
"37723178",
"38012418",
"32361713",
"38168956",
"35152151",
"25704439",
"25891173",
"35070955",
"30881032",
"26755520",
"35108529",
"37322116",
"25428505",
"35697799",
"29070816",
"29360728",
"30765258",
"34534429",
"29863979",
"27093365",
"3787160... | [] | 10.248337 | 5.510309 |
39814310 | 27 | Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers. | Innovative therapeutic strategies are urgently needed to address the ongoing global health concern of hepatobiliary pancreatic malignancies. This review summarizes the latest and most comprehensive research of chimeric antigen receptor (CAR-T) cell engineering immunotherapy for treating hepatobiliary pancreatic cancers... | [
0.010244160890579224,
0.006129745859652758,
0.06155918911099434,
0.06758947670459747,
-0.026508141309022903,
-0.012238552793860435,
0.019033096730709076,
0.056952718645334244,
0.004792299121618271,
0.0062658460810780525,
-0.03348065912723541,
-0.004090859554708004,
-0.03036082349717617,
0.... | 2025-01-16 | 1 | 39814310 | [
"T cell persistence",
"hepatobiliary pancreatic cancers",
"adaptive cell therapy",
"hepatobiliary pancreatic malignancies",
"optimized CAR-T cells",
"CAR-T cell efficacy",
"current CAR-T therapy",
"CAR-T combination therapies",
"Innovative therapeutic strategies",
"CAR-T therapy",
"tumor heterog... | [
"Bioengineering technology",
"Chimeric antigen receptor T (CAR-T) cell immunotherapy",
"Hepatobiliary pancreatic cancers"
] | 0 | 10.1016/j.ijbiomac.2025.139829 | [
"Gao",
"Qu",
"Li",
"Guan",
"Zhang",
"Deng",
"Wang",
"Xing"
] | [
"Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China.",
"Department of Pharmacy, The First Hospital of China Medical University, Shenyang 110001, China.",
"Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.",
"Depar... | [
"39814310"
] | [] | 10.579252 | 3.891303 |
39813621 | 28 | Current developments in T-cell receptor therapy for Acute Myeloid Leukaemia. | T-cell receptor (TCR) therapies are a promising modality for the treatment of cancers, with significant efforts being directed towards acute myeloid leukaemia (AML), a particularly challenging disease. Chimeric antigen receptor (CAR) T-cells targeting single surface antigens have shown remarkable efficacy for B-cell ly... | [
-0.006128888111561537,
0.024012107402086258,
0.06352154910564423,
0.044040437787771225,
-0.017478276044130325,
0.005674693733453751,
0.01777377538383007,
0.02698899619281292,
-0.0032313468400388956,
0.017193719744682312,
-0.02698899619281292,
-0.06334643810987473,
-0.04798043891787529,
0.0... | 2025-01-15 | 1 | 39813621 | [
"cell therapies",
"TCR therapy",
"single surface antigens",
"normal myeloid cells",
"important antigens WT1",
"antigen targets",
"Chimeric antigen receptor",
"AML immunotherapy",
"acute myeloid leukaemia",
"AML",
"heterogenous leukaemia immunophenotypes",
"TCR therapies",
"TCR identification... | [] | 0 | 10.1182/bloodadvances.2024014105 | [
"Gore",
"Blyth",
"Bleakley",
"Lee",
"Micklethwaite",
"Gowrishankar"
] | [
"The University of Sydney, Australia.",
"The University of Sydney, Australia.",
"Fred Hutchinson Cancer Center, Seattle, Washington, United States.",
"Westmead Institute for Medical Research, Australia.",
"Westmead Hospital, Sydney, Australia.",
"The University of Sydney, Sydney, Australia."
] | [
"39813621"
] | [] | 6.819335 | 7.123146 |
39811687 | 29 | Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system. | Chimeric antigen receptor (CAR)-T cell therapy represents a breakthrough for the treatment of hematological malignancies. However, to treat solid tumors and certain hematologic cancers, next-generation CAR-T cells require further genetic modifications to overcome some of the current limitations. Improving manufacturing... | [
0.03141925856471062,
0.012649000622332096,
0.014370604418218136,
0.05116987228393555,
-0.021890662610530853,
-0.028836853802204132,
-0.014059758745133877,
0.032160501927137375,
0.017084520310163498,
-0.04691368713974953,
0.027521738782525063,
0.0010222018463537097,
-0.028310807421803474,
0... | 2025-01-15 | 50 | 39811687 | [
"cell health",
"CAR)-T cell therapy",
"robust cell functionality",
"stem cell memory T cells",
"multi-edited CAR-T cells",
"improved immunological synapse strength",
"edited T cells",
"certain hematologic cancers",
"further genetic modifications",
"higher oxidative phosphorylation levels",
"Solu... | [
"CAR-T",
"CAR-T manufacturing",
"Solupore",
"adoptive cell therapy",
"cell avidity",
"cell cytotoxicity",
"genetic engineering",
"metabolism",
"non-viral transfection",
"stem cell memory"
] | 0 | 10.1016/j.omtm.2024.101389 | [
"O'Sullivan",
"Case",
"McCrudden",
"Hackett",
"Gallagher",
"Martin",
"Johnson",
"Mahadik",
"Kienzle",
"Lim",
"Nashat",
"Srinivasan",
"Lowdell",
"O'Flynn",
"Frankish"
] | [
"Avectas, Cherrywood Business Park, Dublin, Ireland.",
"Avectas, Cherrywood Business Park, Dublin, Ireland.",
"Avectas, Cherrywood Business Park, Dublin, Ireland.",
"Avectas, Cherrywood Business Park, Dublin, Ireland.",
"Avectas, Cherrywood Business Park, Dublin, Ireland.",
"Avectas, Cherrywood Business P... | [
"39811687",
"25317870",
"25319501",
"27111235",
"29385370",
"29385376",
"38326614",
"33824268",
"19525962",
"21926977",
"15931392",
"15980149",
"19805141",
"26942092",
"28060797",
"21737507",
"27226436",
"37433264",
"6329708",
"1912274",
"12648161",
"25939984",
"33941482"... | [] | 8.914077 | 3.011367 |
39810257 | 30 | Construction and characterization of chimeric FcγR T cells for universal T cell therapy. | Several approaches are being explored for engineering off-the-shelf chimeric antigen receptor (CAR) T cells. In this study, we engineered chimeric Fcγ receptor (FcγR) T cells and tested their potential as a versatile platform for universal T cell therapy.
Chimeric FcγR (CFR) constructs were generated using three distin... | [
0.023621099069714546,
0.008070860058069229,
0.03439496457576752,
0.04322266951203346,
-0.026508545503020287,
-0.025198383256793022,
-0.025325583294034004,
0.012847231701016426,
-0.018126044422388077,
0.012402030639350414,
-0.007040537428110838,
-0.027577029541134834,
-0.043070025742053986,
... | 2025-01-15 | 52 | 39810257 | [
"CFR T cells",
"universal T cells",
"universal T cell therapy",
"xenograft mouse models",
"16s3 CFR T cells",
"The CFR T cells",
"the CFR T cells",
"specific MoAbs",
"specific target lysis experiments",
"mouse models",
"CFR",
"tumor xenograft destruction specificity",
"CAR) T cells",
"FcγR... | [
"Breast cancer",
"FcγR",
"Herceptin",
"Lymphoma",
"Off-the-shelf CAR T",
"Ovarian cancer",
"Rituximab",
"Universal CAR T"
] | 0 | 10.1186/s40164-025-00595-x | [
"Zhao",
"Chen",
"Li",
"Chen",
"Li",
"Guo",
"Wang",
"Jiang",
"Song",
"Wang",
"Liu"
] | [
"Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. zhao7851@126.com.",
"State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin,... | [
"39810257",
"21830940",
"36762851",
"38659046",
"37537626",
"39026380",
"39533415",
"38308374",
"35657079",
"35810754",
"35665782",
"32157732",
"34145037",
"35868279",
"32782358",
"34373452",
"34560415",
"31478910",
"26497522",
"26497516",
"2139735",
"2529342",
"32847974"... | [] | 8.330652 | 4.810169 |
39809749 | 31 | Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells. | The excessive cytokine release and limited persistence represent major challenges for chimeric antigen receptor T (CAR-T) cell therapy in diverse tumors. Conventional CARs employ an intracellular domain (ICD) from the ζ subunit of CD3 as a signaling module, and it is largely unknown how alternative CD3 chains potential... | [
0.03684914484620094,
-0.008867732249200344,
0.023103252053260803,
0.05851373448967934,
-0.01638142764568329,
0.004805621691048145,
0.034044355154037476,
0.0022441346663981676,
-0.006836676970124245,
0.010554233565926552,
-0.005954135209321976,
-0.019295023754239082,
-0.019657712429761887,
... | 2025-01-15 | 59 | 39809749 | [
"equipped T cells",
"engineered T cells",
"CAR expression",
"cell therapy",
"CAR",
"CARs",
"CAR design",
"Conventional CARs",
"different CD3 subunits",
"CAR-T cells",
"alternative CD3 chains",
"CAR reconstitution",
"diverse tumor antigens",
"signaling modules",
"CD3",
"limited persiste... | [] | 0 | 10.1038/s41392-024-02096-5 | [
"Wang",
"Wang",
"Zhao",
"Zheng",
"Zhang",
"Meng",
"Dong",
"Liang",
"He",
"Song",
"Su",
"Yan",
"Yang",
"Jia"
] | [
"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an, Shaanxi, China.\nHenan Key Laboratory of Immunology and Targeted Therapy, School of Medical Technology, Xinxiang Medical University, Xinx... | [
"39809749",
"35318469",
"32735779",
"35936003",
"32015021",
"38769449",
"34002066",
"36942414",
"36882513",
"29907163",
"26461090",
"20439624",
"26169254",
"34897277",
"16473826",
"24877875",
"35710755",
"29400710",
"32758419",
"37932456",
"36763234",
"35731927",
"2978975... | [] | 8.516855 | 4.963788 |
39809514 | 32 | Weal and woe of interleukin-18 in the T cell therapy of cancer. | Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a double-edged sword in ... | [
-0.014227522537112236,
0.0036556830164045095,
0.032509125769138336,
0.05168313533067703,
-0.031361743807792664,
-0.02498740516602993,
-0.03273859992623329,
0.001668483018875122,
0.019811443984508514,
0.002033413853496313,
0.019352490082383156,
-0.030469335615634918,
-0.02558659389615059,
0... | 2025-01-15 | 44 | 39809514 | [
"CAR T cell therapies",
"T cell therapy",
"unleashing IL-18",
"remarkable efficacy",
"IL-18",
"hyperinflammatory conditions",
"first clinical trials",
"cytokine help",
"solid cancer",
"Chimeric antigen receptor",
"CAR",
"expectations",
"first",
"a powerful driver",
"what extent",
"a do... | [
"Adoptive cell therapy - ACT",
"Chimeric antigen receptor - CAR",
"Cytokine",
"Immune related adverse event - irAE",
"T cell"
] | 0 | 10.1136/jitc-2024-010545
10.1056/NEJMoa1709866
10.1172/JCI1555
10.1038/s41586-020-2422-6
10.1111/imr.12616
10.1084/jem.20160880
10.1158/2326-6066.CIR-23-0706
10.1200/JCO.2024.42.16_suppl.7004
10.1016/j.celrep.2017.09.002
10.1016/j.celrep.2018.04.051
10.1080/2162402X.2017.1378842
10.1136/ard-2024-225727
10.1002/art.4293... | [
"Kessel",
"Rossig",
"Abken"
] | [
"Translational Inflammation Research, Department of Pediatric Rheumatology & Immunology, University of Münster Faculty of Medicine, Munster, Germany.",
"Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Munster, Germany.\nPrinses Máxima Center for Pediatric Oncology, Utrech... | [
"39809514",
"29385370",
"9502787",
"29247988",
"28264883",
"38592331",
"28954221",
"29768210",
"29296541",
"38777374",
"38924652",
"37748491",
"38381673",
"29295842",
"29326099",
"21576823",
"30674681",
"38287622",
"30592986",
"35705524",
"38781564",
"34525183",
"9469432"... | [] | 7.804799 | 5.34498 |
39806516 | 33 | Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. | The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote tumor growth and therapeutic resistance. Elucidating the intricate interactions between ca... | [
0.008961652405560017,
0.021266866475343704,
0.039736058562994,
0.051358912140131,
-0.015023278072476387,
0.022324522957205772,
0.04628670960664749,
0.010877945460379124,
-0.03480032458901405,
0.01270325668156147,
0.0059365262277424335,
-0.019299397245049477,
0.008398706093430519,
-0.033549... | 2025-01-14 | 1,159 | 39806516 | [
"TME",
"TME modulation",
"cancer cells",
"cancer progression",
"therapeutic resistance",
"cancer therapy",
"epithelial cells",
"diverse cell types",
"therapeutic challenges",
"extracellular matrix components",
"various components",
"resistance mechanisms",
"the various TME components",
"me... | [
"Cancer",
"Cancer-associated fibroblasts (CAFs)",
"Chimeric antigen-receptor (CAR) T-cell therapy",
"Dendritic cells (DCs)",
"Epithelial-mesenchymal transition (EMT)",
"Extracellular matrix (ECM)",
"Metastasis",
"Myeloid-derived suppressor cells (MDSCs)",
"Natural killer (NK) cells",
"T-cell recep... | 0 | 10.1186/s13045-024-01634-6 | [
"Glaviano",
"Lau",
"Carter",
"Lee",
"Lam",
"Okina",
"Tan",
"Tan",
"Ang",
"Carbone",
"Yee",
"Shanmugam",
"Huang",
"Sethi",
"Tan",
"Lim",
"Huang",
"Ungefroren",
"Giovannetti",
"Tang",
"Bruno",
"Luo",
"Andersen",
"Qian",
"Ishihara",
"Radisky",
"Elias",
"Yadav",
"... | [
"Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, 90123, Palermo, Italy.",
"Division of Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre Singapore, Singapore, 169610, Singapore.\nDepartment of Physiology, Yong... | [
"39806516",
"35988567",
"36791168",
"38050068",
"19109576",
"38849014",
"35411083",
"38227149",
"30459476",
"19945376",
"30459476",
"30594349",
"36787696",
"38378518",
"32566256",
"33257838",
"24556840",
"27840647",
"20531305",
"38503384",
"25852822",
"26791236",
"2320116... | [] | 10.562271 | 5.159496 |
39806405 | 34 | Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach. | Multiple myeloma (MM) is an incurable plasma cell malignancy with increasing global incidence. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA has shown efficacy in relapsed or refractory MM, but it faces resistance due to antigen loss and the tumor microenvironment. Bispecific T-cell engaging (BITE) anti... | [
0.017284415662288666,
0.005753311328589916,
0.045292023569345474,
0.02209516428411007,
-0.06375158578157425,
-0.005226944573223591,
0.01157394889742136,
0.02857069857418537,
-0.005052508786320686,
-0.02263377234339714,
-0.0018514645053073764,
-0.038143228739500046,
-0.04355379194021225,
0.... | 2025-01-14 | 64 | 39806405 | [
"MM cells",
"MM cell lines",
"T cells",
"SupT-1 cells",
"current MM treatments",
"MM",
"Bispecific T-cell",
"clinical challenges",
"an incurable plasma cell malignancy",
"significant anti-tumor activity",
"continuous infusion",
"antigen loss",
"CAR) T-cell therapy",
"αB7-H3-αCD3 ENG T cell... | [
"B7-H3",
"BITE",
"Bispecific T-cell engager",
"CD276",
"ENG T cells",
"Multiple myeloma",
"T cells secreting BITE"
] | 0 | 10.1186/s12967-024-05923-z | [
"Rujirachaivej",
"Siriboonpiputtana",
"Choomee",
"Supimon",
"Sangsuwannukul",
"Songprakhon",
"Natungnuy",
"Luangwattananun",
"Yuti",
"Junking",
"Yenchitsomanus"
] | [
"Graduate Program in Clinical Pathology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.",
"Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.",
"Siriraj Center of Research Excellence for Cancer Immu... | [
"39806405",
"28726797",
"33498356",
"35560063",
"27705267",
"33918370",
"28688533",
"21187443",
"25287778",
"31042825",
"35658469",
"33626253",
"34175021",
"33272302",
"37507805",
"33922005",
"37591844",
"33941237",
"28249141",
"36941881",
"37982732",
"37497430",
"2720929... | [] | 4.824218 | 6.221375 |
39805956 | 35 | ETV7 limits the antiviral and antitumor efficacy of CD8 | Terminal exhaustion is a critical barrier to antitumor immunity. By integrating and analyzing single-cell RNA-sequencing and single-cell assay for transposase-accessible chromatin with sequencing data, we found that ETS variant 7 (ETV7) is indispensable for determining CD8 | [
0.003866758896037936,
0.02595425210893154,
0.057287223637104034,
0.04925774782896042,
-0.03723926842212677,
-0.0032121120020747185,
0.03844883665442467,
0.044856976717710495,
-0.009637944400310516,
-0.017088372260332108,
0.022068191319704056,
0.0630519762635231,
0.01823360100388527,
-0.021... | 2025-01-14 | 68 | 39805956 | [
"Terminal exhaustion",
"data",
"transposase-accessible chromatin",
"Terminal",
"immunity",
"RNA",
"single-cell RNA-sequencing and single-cell assay",
"CD8",
"a critical barrier",
"that ETS",
"7",
"we"
] | [] | 0 | 10.1038/s43018-024-00892-0
10.1016/j.immuni.2011.07.010
10.1038/ni.3031
10.1038/2201352a0
10.1016/bs.pmbts.2018.11.002
10.1146/annurev-immunol-041015-055318
10.1038/s41577-021-00574-3
10.1016/j.immuni.2016.07.011
10.1016/j.ccell.2017.02.008
10.1016/j.ccell.2018.03.012
10.1016/j.cell.2018.10.038
10.1038/nature19330
10.1... | [
"Cheng",
"Xiao",
"Peng",
"Zhang",
"Qin",
"Wang",
"Shi",
"Yan",
"Zhao",
"Zheng",
"He",
"Wang",
"Zhang",
"Li",
"Zhu",
"Jiang"
] | [
"State Key Laboratory of Molecular Oncology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China.\nDepartment of Pathology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases,... | [
"39805956",
"21867926",
"25396352",
"4302696",
"31383402",
"30676822",
"34253904",
"27521269",
"28292435",
"29634943",
"30388456",
"27501248",
"30635237",
"33303615",
"34580473",
"36216928",
"33972771",
"29449531",
"27860544",
"34914499",
"35668194",
"31375813",
"32661364... | [] | 10.218875 | 5.228067 |
39805660 | 36 | CD93 blockade promotes effector T-cell infiltration and facilitates adoptive cell therapy in solid tumors. | Adaptive cellular therapy (ACT), particularly chimeric antigen receptor (CAR)-T cell therapy, has been successful in the treatment of hemopoietic malignancies. However, poor trafficking of administered effector T cells to the tumor poses a great hurdle for this otherwise powerful therapeutic approach in solid cancers. ... | [
0.02905958704650402,
0.0217145849019289,
-0.0013263520086184144,
0.0579712875187397,
-0.003962110728025436,
-0.035665158182382584,
0.03827781230211258,
0.009316814132034779,
0.018005112186074257,
-0.0024647656828165054,
-0.0008950180490501225,
0.0036509342025965452,
-0.05264739319682121,
0... | 2025-01-14 | 33 | 39805660 | [
"effector T cells",
"CD93 blockade",
"administered effector T cells",
"CD93",
"pmel-1 transgenic T cells",
"CAR)-T cell therapy",
"tumor vascular maturation",
"tumor vascular functions",
"tumor vasculature",
"immune checkpoint blockade therapy",
"improved effector T-cell infiltration",
"tumors... | [
"Adoptive cell therapy - ACT",
"Immunotherapy",
"Solid tumor",
"T cell",
"Tumor infiltrating lymphocyte - TIL"
] | 0 | 10.1136/jitc-2024-010554
10.1126/science.aaa4967
10.1126/science.aar6711
10.1016/j.molimm.2014.09.017
10.1158/1535-7163.MCT-23-0310
10.1056/NEJMoa1103849
10.1056/NEJMoa1707447
10.1056/NEJMoa2210233
10.1200/JCO.21.00612
10.1007/s40291-024-00749-3
10.1158/0008-5472.CAN-12-4354
10.1158/1078-0432.CCR-18-2722
10.1016/j.biop... | [
"Sun",
"Yee",
"Fujiwara",
"Dickinson",
"Guo",
"Sun",
"Hu",
"Davila",
"Schulick",
"Zhu"
] | [
"Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.",
"Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.",
"Division of Surgical Oncology, Department of Surgery, U... | [
"39805660",
"25838374",
"29567707",
"25451975",
"37903371",
"21830940",
"29226797",
"36477031",
"33979178",
"39404764",
"23440426",
"30518633",
"38972151",
"35104158",
"38563600",
"36775787",
"28561728",
"35193894",
"37442359",
"25196648",
"25344227",
"25665467",
"2919843... | [] | 9.682021 | 5.138822 |
39805063 | 37 | Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy. | Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially s... | [
0.03733886405825615,
0.04013817757368088,
0.08164294809103012,
0.0665222555398941,
-0.03998388350009918,
-0.005422290880233049,
0.0274420827627182,
0.035090599209070206,
0.008678971789777279,
0.0353550985455513,
-0.02118220180273056,
-0.027640458196401596,
-0.028411922976374626,
0.02805925... | 2025-01-13 | 1 | 39805063 | [
"metastatic CRC",
"CRC",
"CAR-T cell therapy",
"CAR-T cell therapies",
"tumor heterogeneity",
"solid tumors",
"conventional treatment modalities",
"tumor infiltration",
"T-cell persistence",
"significant potential",
"Colorectal cancer",
"immune checkpoint inhibitors",
"limited options",
"h... | [] | 0 | 10.1200/JCO-24-02081 | [
"Ouladan",
"Orouji"
] | [
"Department of Pathology, McGill University, Montreal, QC, Canada.",
"Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada."
] | [
"39805063"
] | [] | 10.7438 | 5.124182 |
39801735 | 38 | Monovalent Anti-CD3 Antibodies Effectively Eliminate the TCR-Positive Fraction of TCR-Deleted Allogeneic CAR-T Cells to Prevent GVHD. | Chimeric antigen receptor-transduced T (CAR-T) cell therapy is an effective cell therapy against advanced hematological tumors. However, the use of autologous T cells limits its timely and universal generation. Allogeneic CAR-T cell therapy may be a good alternative as a ready-to-use therapeutic. Graft-versus-host dise... | [
0.016106318682432175,
0.006051407195627689,
0.04679601266980171,
0.06087173521518707,
-0.03791215270757675,
-0.06313308328390121,
-0.023201867938041687,
0.01897915080189705,
0.0019483915530145168,
-0.01897915080189705,
0.0009958285372704268,
0.0000984291109489277,
-0.04684216156601906,
0.0... | 2025-01-13 | 30 | 39801735 | [
"autologous T cells",
"Allogeneic CAR-T cell therapy",
"monovalent anti-CD3 Abs",
"allogeneic CAR-T cells",
"TCR deletion",
"TCR-positive cells",
"TCR",
"an effective cell therapy",
"advanced hematological tumors",
"costly, large-scale magnetic cell separation",
"the remaining TCR-positive cells... | [
"Allogeneic cells",
"Anti-CD3 antibody",
"Apoptosis",
"Graft-versus-host disease",
"Receptors, chimeric antigen",
"T-lymphocytes"
] | 0 | 10.4110/in.2024.24.e43 | [
"Kim",
"Kim",
"Lee",
"Park",
"Choi"
] | [
"Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 03080, Korea.\nDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea.",
"Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Korea.",
"Asan Insti... | [
"39801735",
"29567707",
"36813894",
"37979380",
"29226764",
"29226797",
"37554322",
"22466705",
"26183927",
"28123068",
"28225754",
"29605708",
"33308471",
"36288281",
"8482839",
"11086054",
"37153038",
"26502778",
"23136200",
"23524462",
"32671047",
"37196643",
"1944559"... | [] | 8.272791 | 3.390259 |
39800376 | 39 | Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. | The ability of immune cells to expand numerically after infusion distinguishes adoptive immunotherapies from traditional drugs, providing unique therapeutic advantages as well as the potential for unmanageable toxicities. Here, we describe a case of lethal hyperleukocytosis in a patient with neuroblastoma treated on ph... | [
0.019580690190196037,
0.008847992867231369,
0.04879993945360184,
0.051861003041267395,
-0.023337451741099358,
-0.020516717806458473,
-0.02470354549586773,
0.020440824329853058,
-0.001392973936162889,
0.016089560464024544,
0.01576068438589573,
-0.0013471212005242705,
-0.04819278419017792,
0... | 2025-01-13 | 1 | 39800376 | [
"cell therapy products",
"immune cells",
"immune cell activation",
"autologous natural killer T cells",
"autologous peripheral blood mononuclear cells",
"known clinical significance",
"clonal expansion",
"lymphocyte expansion",
"unique therapeutic advantages",
"distinct gene expression",
"unmana... | [
"Adoptive cell therapy - ACT",
"Chimeric antigen receptor - CAR",
"Neuroblastoma"
] | 0 | 10.1136/jitc-2024-010156 | [
"Tian",
"Courtney",
"Yu",
"Bhar",
"Xu",
"Barragán",
"Martinez Amador",
"Ghatwai",
"Wood",
"Schady",
"Montalbano",
"Reddy",
"Roche",
"de la Cerda",
"Parsons",
"Di Pierro",
"Bushman",
"Heczey",
"Metelitsa"
] | [
"Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.",
"Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.",
"Center for Advanced Innate Cell Therapy, Department of Pediatrics, Baylor... | [
"39800376"
] | [] | 11.293136 | 5.889207 |
39798497 | 40 | Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives. | Cancer remains one of the most pressing health challenges worldwide. Recently, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising approach for treating hematological cancers. However, the translation of CAR-T cell therapy to solid tumors faces formidable obstacles, notably the immunosuppressive t... | [
0.021029463037848473,
0.010762004181742668,
0.025469141080975533,
0.03790023922920227,
-0.013723663054406643,
-0.05071348696947098,
0.039293959736824036,
0.03785528242588043,
-0.003211741801351309,
-0.019984170794487,
-0.015308459289371967,
-0.027110135182738304,
-0.05858127027750015,
-0.0... | 2025-01-12 | 1 | 39798497 | [
"cell culture media",
"CAR)-T cell therapy",
"cancer cells",
"culture media optimization",
"solid tumors",
"basic culture media",
"CAR-T cell therapy",
"CAR-T cell phenotypes",
"CAR-T cells",
"specific additives",
"hematological cancers",
"additives",
"cancer patients",
"Cancer",
"the cu... | [
"CAR-T cell therapy",
"Culture media additives",
"Memory phenotype",
"T cell exhaustion",
"immunotherapy"
] | 0 | 10.1016/j.retram.2024.103491 | [
"Chen",
"Xu",
"Guo",
"Zhou"
] | [
"Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China.",
"Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China.",
"Jiangsu Key Laboratory ... | [
"39798497"
] | [] | 9.908972 | 4.780149 |
39798230 | 41 | CAR-T cell therapy for breast cancer: Current status and future perspective. | Within the expanding therapeutic landscape for breast cancer (BC), metastatic breast cancer (MBC) remains virtually incurable and tend to develop resistance to conventional treatments ultimately leading to metastatic progression and death. Cellular immunotherapy (CI), particularly chimeric antigen receptor-engineered T... | [
0.05426102131605148,
0.026762327179312706,
0.06263719499111176,
0.05283430963754654,
-0.0460919514298439,
-0.015141540206968784,
0.024783341214060783,
0.010182570666074753,
-0.020917415618896484,
0.03732458874583244,
0.00858327466994524,
-0.02230961062014103,
-0.016775354743003845,
0.01076... | 2025-01-12 | 1 | 39798230 | [
"T cell",
"T cell exhaustion",
"CAR-T cell therapy",
"universal CAR platforms",
"metastatic breast cancer",
"CAR-T cells",
"antigen escape",
"Possible approaches",
"armored CARs",
"breast cancer",
"antigen",
"CAR",
"BC therapy",
"chemokine receptor engineering",
"hematological cancers",
... | [
"Breast cancer",
"CAR",
"Clinical trial",
"Immunotherapy",
"T cell",
"Tumor antigen"
] | 0 | 10.1016/j.ctrv.2024.102868 | [
"Buono",
"Capozzi",
"Caputo",
"Lauro",
"Cianniello",
"Piezzo",
"Cocco",
"Martinelli",
"Verrazzo",
"Tafuro",
"Calderaio",
"Calabrese",
"Nuzzo",
"Pagliuca",
"Laurentiis"
] | [
"Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy.",
"Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy.",
"Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy.",
"Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy.",
"Istitut... | [
"39798230"
] | [] | 10.293876 | 4.331953 |
39798090 | 42 | Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets. | Metabolic reprogramming in both immune and cancer cells plays a crucial role in the antitumor immune response. Recent studies indicate that cancer metabolism not only sustains carcinogenesis and survival via altered signaling but also modulates immune cell function. Metabolic crosstalk within the tumor microenvironment... | [
0.011872739531099796,
0.018889930099248886,
0.0411037914454937,
0.043602172285318375,
-0.033261049538850784,
0.024940356612205505,
0.03769296035170555,
0.04966346174478531,
-0.005936369765549898,
-0.011052618734538555,
-0.02268095128238201,
-0.03486870229244232,
-0.0036905426532030106,
0.0... | 2025-01-12 | 1 | 39798090 | [
"immune cells",
"modulates immune cell function",
"immune cell functionality",
"antitumor immune responses",
"cancer immunotherapy",
"cancer metabolism",
"CAR)-T cells",
"cancer",
"Metabolic",
"chimeric antigen receptor",
"nutrient competition",
"existing treatment protocols",
"the antitumor... | [
"CP: Cancer",
"CP: Metabolism",
"antitumor activity of immune cells",
"cancer",
"metabolism",
"therapeutic strategies",
"tumor microenvironment"
] | 0 | 10.1016/j.celrep.2024.115206 | [
"Ricci"
] | [
"Université Côte d'Azur, INSERM, C3M, Nice, France; Équipe labellisée LIGUE Contre le Cancer, Nice, France. Electronic address: ricci@unice.fr."
] | [
"39798090"
] | [] | 10.449526 | 4.880123 |
39796666 | 43 | Engineered Cellular Therapies for the Treatment of Thoracic Cancers. | Thoracic malignancies (lung cancers and malignant pleural mesothelioma) are prevalent worldwide and are associated with high morbidity and mortality. Effective treatments are needed for patients with advanced disease. Cell therapies are a promising approach to the treatment of advanced cancers that make use of immune e... | [
0.0007365582860074937,
0.025262849405407906,
0.06376176327466965,
0.05237259343266487,
-0.002189062302932143,
-0.02825305610895157,
-0.004938788246363401,
0.03221068158745766,
0.006546574179083109,
0.013356990180909634,
-0.00806916132569313,
-0.02827504277229309,
-0.027505503967404366,
0.0... | 2025-01-11 | 266 | 39796666 | [
"Cell therapies",
"effective cell therapy",
"immune effector cells",
"antitumor immune cells",
"NK cells",
"additional cell therapy platforms",
"immunosuppressive cells",
"Induced pluripotent stem cells",
"advanced cancers",
"most other solid tumors",
"several hematologic cancers",
"TCR-T cell... | [
"CAR-T cells",
"NK cells",
"cell therapy",
"lung cancer",
"mesothelioma"
] | 0 | 10.3390/cancers17010035
10.1016/S0140-6736(21)00312-3
10.1200/OP.21.00426
10.1016/j.ccell.2020.07.013
10.1182/blood.2022016205
10.1126/science.aaa4967
10.1056/NEJM198512053132327
10.1056/NEJM198704093161501
10.1126/science.3489291
10.1056/NEJM198812223192527
10.1136/jitc-2021-002723
10.1038/s41571-023-00832-4
10.1056/N... | [
"Erickson",
"Manning",
"Kumar",
"Patel"
] | [
"Internal Medicine Residency Program, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.",
"Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.",
"Division of Hematology, Oncol... | [
"39796666",
"34273294",
"34491782",
"32822573",
"36327161",
"25838374",
"3903508",
"3493432",
"3489291",
"3264384",
"34301811",
"37904019",
"36477031",
"38477966",
"38454126",
"37018492",
"36813894",
"36791198",
"36416736",
"29107016",
"36829563",
"32685008",
"36384203",
... | [] | 10.491421 | 4.53794 |
39794936 | 44 | Preclinical model for evaluating human TCRs against chimeric syngeneic tumors. | The adoptive cell transfer (ACT) of T cell receptor (TCR)-engineered T cells targeting the HLA-A2-restricted epitope NY-ESO-1
We compared the function of a supraphysiological affinity A2/NY TCR (wtc51m), a computationally designed TCR in an optimal affinity range (DMβ), and a near non-binding TCR (V49I), engineered in ... | [
0.00730766961351037,
-0.01680149883031845,
0.007037470117211342,
0.03971933573484421,
-0.023949505761265755,
-0.011630862951278687,
0.016690963879227638,
0.04875873774290085,
0.0012450672220438719,
-0.004507419653236866,
0.0024287255946546793,
-0.0223037451505661,
-0.03335736319422722,
0.0... | 2025-01-11 | 82 | 39794936 | [
"mouse tumor cell lines",
"T cell receptor",
"tumor control",
"tumors",
"TCR",
"coengineered TCR-T cells",
"DMβ-T cell transfer",
"human β2",
"A2Kb",
"human TCRs",
"B16 melanoma",
"DMβ-T cells",
"NY",
"HLA",
"ACT studies",
"a near non-binding TCR",
"(TCR)-engineered T cells",
"GS l... | [
"Adoptive cell therapy - ACT",
"Immunotherapy",
"T cell",
"T cell Receptor - TCR",
"Tumor microenvironment - TME"
] | 0 | 10.1136/jitc-2024-009504
10.1038/s41586-018-0130-2
10.1038/s41586-021-03704-y
10.1126/science.aak9510
10.1038/s41587-021-01072-6
10.1056/NEJM198812223192527
10.1158/1078-0432.CCR-11-0116
10.1093/annonc/mdz398
10.1158/1078-0432.CCR-13-0380
10.1038/s41591-018-0040-8
10.1038/s41591-021-01462-y
10.1126/science.1251102
10.1... | [
"Semilietof",
"Stefanidis",
"Gray-Gaillard",
"Pujol",
"D'Esposito",
"Reichenbach",
"Guillaume",
"Zoete",
"Irving",
"Michielin"
] | [
"Swiss Institute of Bioinformatics, Lausanne, Switzerland.\nDepartment of Oncology, Ludwig Institute for Cancer Research Lausanne, University of Lausanne, Epalinges, Switzerland.",
"Department of Oncology, Ludwig Institute for Cancer Research Lausanne, University of Lausanne, Epalinges, Switzerland.",
"Swiss In... | [
"39794936",
"29769722",
"34290406",
"28408606",
"34782741",
"3264384",
"21498393",
"31566658",
"23690483",
"29867227",
"34385708",
"24812403",
"29853601",
"25823737",
"38093023",
"29634943",
"22949370",
"37891435",
"38554725",
"39152243",
"37069267",
"31182835",
"37314354... | [] | 9.368359 | 4.713792 |
39794934 | 45 | Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies. | Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative modality in the treatment of patients with cancer. However, it is increasingly evident that this therapeutic approach is not without its challenges. The unique nature of CAR-T cells as living drugs introduces a distinct set of side effects. ... | [
0.024585191160440445,
0.03014983795583248,
0.04257435351610184,
0.04271826893091202,
-0.0521925613284111,
-0.00530080683529377,
0.03995992988348007,
0.00310912705026567,
0.01192681584507227,
0.01375571358948946,
0.016334161162376404,
-0.03314803168177605,
-0.036362096667289734,
-0.01131518... | 2025-01-11 | 59 | 39794934 | [
"CAR)-T cell therapy",
"neuropsychological symptoms",
"neuropsychological assessments",
"CAR-T cell therapy",
"empirical studies",
"study characteristics",
"observational studies",
"other symptoms",
"different CAR-T cell products",
"CAR-T cells",
"immune effector cell-associated neurotoxicity sy... | [
"Chimeric antigen receptor - CAR",
"Cytokine release syndrome",
"Encephalitis",
"Immune effector cell-associated neurotoxicity syndrome - ICANS",
"Neurotoxicity"
] | 0 | 10.1136/jitc-2024-009174
10.1056/NEJMoa1707447
10.3389/fimmu.2022.876339
10.1080/14712598.2023.2248878
10.1056/NEJMc2309399
10.1182/blood.2021014892
10.1016/S1470-2045(22)00339-4
10.3324/haematol.2023.283940
10.1358/dot.2023.59.1.3509751
10.1016/S2352-3026(21)00057-0
10.6004/jadpro.2019.10.4.11
10.1016/j.annonc.2020.10... | [
"Fleischer",
"Kurth",
"Duell",
"Topp",
"Strunz",
"Mersi",
"Rasche",
"Sanges",
"Hudecek",
"Einsele",
"Maatouk"
] | [
"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany Fleischer_A@ukw.de.",
"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany.",
"Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany.",
"Department of Internal Med... | [
"39794934",
"29226797",
"35493513",
"37599463",
"37733322",
"35507688",
"35839786",
"37731379",
"36811414",
"34048683",
"33520343",
"33098993",
"29208604",
"38444031",
"33335028",
"33140239",
"29025771",
"29880584",
"34794490",
"30501490",
"34893771",
"32961131",
"3089159... | [] | 6.147024 | 4.052469 |
39793572 | 46 | CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. | Clinical application of autologous chimeric antigen receptor (CAR)-T cells is complicated by limited targeting of cancer types, as well as the time-consuming and costly manufacturing process. We develop CD70-targeted, induced pluripotent stem cell-derived CAR-natural killer (NK) (70CAR-iNK) cells as an approach for uni... | [
0.009228155948221684,
0.010516847483813763,
0.01918470300734043,
0.05737481266260147,
-0.04112608730792999,
-0.057150691747665405,
-0.019778622314333916,
0.06042284891009331,
-0.0041882493533194065,
-0.00007931759319035336,
0.001002238248474896,
-0.015654807910323143,
-0.0558507926762104,
... | 2025-01-11 | 1 | 39793572 | [
"iNK cells",
"CAR)-T cells",
"universal immune cell therapy",
"CD70 gene knockout",
"autologous chimeric antigen receptor",
"70CAR-iNK cells",
"next-generation universal immune cell therapy",
"recipient alloreactive T cells",
"70CAR",
"alloreactive T cells",
"cancer types",
"CD70",
"gene-edi... | [
"CD70",
"allogeneic rejection",
"chimeric antigen receptor",
"induced pluripotent stem cell",
"multiplex gene editing",
"natural killer cell"
] | 0 | 10.1016/j.xcrm.2024.101889 | [
"Wang",
"Wang",
"He",
"Mo",
"Zhao",
"Liang",
"Hu",
"Wang",
"Yue",
"Mo",
"Zhou",
"Hong",
"Zhou",
"Feng",
"Chen",
"Shen",
"Song",
"Zeng",
"Jia",
"Shao",
"Zhang",
"Xu",
"Wang",
"Hu",
"Yang",
"Huang"
] | [
"Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 311121, China; Institute of Hematology, Zhejiang University, Hangzhou 310058, China; Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou... | [
"39793572"
] | [] | 11.261157 | 5.80868 |
39792660 | 47 | Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. | Chimeric antigen receptor T cells (CART) targeting CD19 through CD28.ζ signaling induce rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB.ζ-CART. We reasoned that molecular dynamics at the CART immune synapse (CARIS) could explain differences in their tumor rejection kinetics.... | [
0.02868328057229519,
0.016721079126000404,
-0.0005586966290138662,
0.06683230400085449,
-0.04522232711315155,
0.030035529285669327,
-0.011916694231331348,
0.0056495401076972485,
-0.02635585330426693,
-0.002971047069877386,
0.007664911448955536,
0.014510671608150005,
-0.030763663351535797,
... | 2025-01-10 | 124 | 39792660 | [
"fast CART recovery",
"CART",
"lengthy CARIS",
"CARIS",
"persistent tumor control",
"CARIS membrane lipid rafts",
"mLRs",
"Chimeric antigen receptor T cells",
"serial killing",
"low target site density",
"induce rapid lysis",
"cooperative killing",
"CD28.ζ",
"molecular dynamics",
"leukem... | [] | 0 | 10.1126/sciadv.adq8114 | [
"Gad",
"Morris",
"Godret-Miertschin",
"Montalvo",
"Kerr",
"Berger",
"Lee",
"Saadeldin",
"Abu-Arja",
"Xu",
"Vasileiou",
"Brock",
"Fousek",
"Sheha",
"Srinivasan",
"Li",
"Saeedi",
"R Levental",
"Leen",
"Mamonkin",
"Carisey",
"Varadarajan",
"Hegde",
"Joseph",
"Levental",
... | [
"Interdepartmental Translational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, TX 77030, USA.\nTexas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.\nCenter for Cell and Gene Therapy, Texas Children's Hospital, Houston ... | [
"39792660",
"37059073",
"35650421",
"34088999",
"34230645",
"25319501",
"25317870",
"31650026",
"23515080",
"34560014",
"29385376",
"24553386",
"26333935",
"35110735",
"36750666",
"36912764",
"36202524",
"37055515",
"37890589",
"37971169",
"34971569",
"26514825",
"3379525... | [] | 7.731435 | 5.378867 |
39792088 | 48 | Cancer immunotherapy in progress-an overview of the past 130 years. | Since the first approval of an immune-checkpoint inhibitor, we have witnessed the clinical success of cancer immunotherapy. Adoptive T-cell therapy with chimeric antigen-receptor T (CAR-T) cells has shown remarkable efficacy in hematological malignancies. Concurrently with these successes, the cancer immunoediting conc... | [
0.009482025168836117,
-0.009968573227524757,
0.047296974807977676,
0.05657533183693886,
-0.03672870621085167,
-0.03743023797869682,
0.02017476223409176,
0.03625347092747688,
0.0005077635869383812,
0.01165451854467392,
0.035189855843782425,
-0.032315827906131744,
-0.06024141237139702,
0.002... | 2025-01-10 | 1 | 39792088 | [
"cancer immunotherapy",
"tumor heterogeneity",
"tumors",
"past failures",
"remarkable efficacy",
"recent breakthroughs",
"Adoptive T-cell therapy",
"hematological malignancies",
"issues",
"the cancer immunosurveillance concept",
"the cancer immunoediting concept",
"patients",
"approaches",
... | [
"CAR-T therapy",
"immune checkpoint inhibitor",
"tumor heterogeneity",
"tumor immunology"
] | 0 | 10.1093/intimm/dxaf002 | [
"Ikeda"
] | [
"Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4, Sakamoto, Nagasaki, 852-8523, Japan.\nLeading Medical Research Core Unit, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4, Sakamoto, Nagasaki, 852-8523, Japan."
] | [
"39792088"
] | [] | 10.589274 | 4.138658 |
39791742 | 49 | CAR-T Therapy Beyond B-Cell Hematological Malignancies. | Despite the advances of CAR-T cells in certain hematological malignancies, mostly from B-cell derivations such as non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, a significant portion of other hematological and non-hematological pathologies can benefit from this innovative treatment, as the re... | [
0.009539337828755379,
0.007050318643450737,
0.0638011023402214,
0.03913925960659981,
-0.03009658306837082,
-0.023657100275158882,
-0.025438234210014343,
0.0064680250361561775,
-0.009756270796060562,
-0.0028415352571755648,
-0.026648491621017456,
-0.039458949118852615,
-0.04270152375102043,
... | 2025-01-10 | 102 | 39791742 | [
"different molecular engineering platforms",
"acute lymphoblastic leukemia",
"certain hematological malignancies",
"non-Hodgkin lymphomas",
"non-Hodgkin",
"other hematological and non-hematological pathologies",
"acute myeloid",
"autoimmune diseases",
"hematological B-cell diseases",
"clinical stu... | [
"CAR-T in hematology",
"CAR-T in solid neoplasia",
"infectious and autoimmune disease",
"tumor immunosuppression",
"tumor microenvironment"
] | 0 | 10.3390/cells14010041
10.1056/NEJMoa1707447
10.1056/NEJMoa1709866
10.1016/S0140-6736(21)01222-8
10.1016/S0140-6736(20)31366-0
10.1056/NEJMoa1817226
10.1111/imr.12126
10.1016/j.jocit.2016.08.001
10.1016/j.annonc.2021.12.003
10.1182/blood.2019001463
10.1016/j.tranon.2020.100838
10.1038/mt.2014.164
10.1038/s41375-017-0008... | [
"Canichella",
"de Fabritiis"
] | [
"Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy.",
"Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy.\nDepartment of Biomedicina e Prevenzione, Tor Vergata University, 00133 Rome, Italy."
] | [
"39791742",
"29226797",
"29385370",
"34097852",
"32888407",
"31042825",
"24329792",
"34923107",
"31697826",
"32745961",
"25174587",
"29479065",
"33833386",
"29409351",
"34531250",
"31043341",
"28246194",
"34638268",
"17609428",
"28676343",
"33495835",
"29716633",
"3628970... | [] | 6.807213 | 6.533801 |
39791458 | 50 | Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. | Using immunotherapeutic agents like inotuzumab ozogamicin (InO), blinatumomab, or chimeric antigen receptor T (CAR T)-cell therapy in frontline adult B-cell acute lymphoblastic leukemia (B-ALL) therapy is promising. These agents are mostly well tolerated and have different toxicity profiles than conventional chemothera... | [
0.005498818587511778,
0.023872919380664825,
0.0651567354798317,
0.0862741470336914,
-0.0252628643065691,
-0.029237620532512665,
0.031578581780195236,
0.027286820113658905,
0.011851112358272076,
-0.006492507643997669,
0.0027311204466968775,
-0.013448330573737621,
-0.03977194428443909,
0.023... | 2025-01-10 | 1 | 39791458 | [
"allogeneic hematopoietic stem cell transplantation",
"consolidation therapy",
"blinatumomab administration",
"T)-cell therapy",
"based measurable residual disease analysis",
"different toxicity profiles",
"CAR T-cell therapies",
"blinatumomab",
"conventional chemotherapy",
"Newer generation CAR T... | [
"CAR T-cell therapy",
"Inotuzumab ozogamicin",
"NGS",
"blinatumomab",
"measurable residual disease"
] | 0 | 10.1080/10428194.2025.2449582 | [
"Senapati",
"Kantarjian",
"Habib",
"Haddad",
"Jain",
"Short",
"Jabbour"
] | [
"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.",
"Department of Leukemi... | [
"39791458"
] | [] | 6.47795 | 6.393093 |
39789380 | 51 | Adoptive cell therapies in thoracic malignancies: a comprehensive review. | This review aims to summarize recent studies and findings within adoptive cell therapies, including tumor-infiltrating lymphocytes, genetically engineered T cell receptors, and chimeric antigen receptor T cells, in the treatment of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, and... | [
0.023807097226381302,
0.0025149944704025984,
0.05594440549612045,
0.038419101387262344,
-0.02322671376168728,
-0.00009841979044722393,
0.011362995952367783,
0.011960449628531933,
0.006037124898284674,
0.008654540404677391,
-0.015442749485373497,
-0.0332980714738369,
-0.025195466354489326,
... | 2025-01-10 | 96 | 39789380 | [
"adoptive cell therapies",
"chimeric antigen receptor T cells",
"small cell lung cancer",
"non-small cell lung cancer",
"new cellular therapies",
"thoracic malignancies",
"recent studies",
"genetically engineered T cell receptors",
"developing strategies",
"malignant pleural mesothelioma",
"sign... | [
"Adoptive cell therapies",
"CAR-T",
"MPM",
"NSCLC",
"SCLC",
"TCR",
"Tumor-infiltrating lymphocytes (TILs)"
] | 0 | 10.1007/s12094-024-03834-5
10.3322/caac.21660
10.6004/jnccn.2022.0025
10.1200/JCO.22.01990
10.1200/JCO.22.01989
10.1007/s12094-023-03216-3
10.1056/NEJMoa1809064
10.1200/JCO.20.00793
10.1016/S0140-6736(19)32222-6
10.1016/j.annonc.2021.02.025
10.1016/j.annonc.2022.01.074
10.1007/s00428-021-03031-7
10.1158/2159-8290.CD-12... | [
"Garitaonaindia",
"Martínez-Cutillas",
"Uribarren",
"Redondo",
"Calvo",
"Serna-Blasco",
"Provencio"
] | [
"Medical Oncology Department, Puerta de Hierro University Hospital, C/ Manuel de Falla, 1, 28222, Majadahonda, Madrid, Spain. yagogarita@gmail.com.",
"Medical Oncology Department, Puerta de Hierro University Hospital, C/ Manuel de Falla, 1, 28222, Majadahonda, Madrid, Spain.",
"Medical Oncology Department, Puer... | [
"39789380",
"33538338",
"35545176",
"36735893",
"36809080",
"37418123",
"30280641",
"32468956",
"31590988",
"33737119",
"35124183",
"33475835",
"23550147",
"37425981",
"11970966",
"37509394",
"35088475",
"32039010",
"33025047",
"37345192",
"34032893",
"37376985",
"3647925... | [] | 10.338913 | 4.398136 |
39786986 | 52 | The bidirectional interplay between T cell-based immunotherapies and the tumor microenvironment. | T cell-based therapies, including Tumor Infiltrating Lymphocyte Therapy (TIL), T cell receptor engineered T cells (TCR T), and Chimeric Antigen Receptor T cells (CAR T), are powerful therapeutic approaches for cancer treatment. While these therapies are primarily known for their direct cytotoxic effects on cancer cells... | [
0.003042378230020404,
0.004777819383889437,
0.043386027216911316,
0.02836696431040764,
-0.027702782303094864,
0.006866776384413242,
0.04077215492725372,
0.015136903151869774,
-0.044393014162778854,
0.029716750606894493,
-0.006925695575773716,
-0.006379352882504463,
-0.01945408061146736,
-0... | 2025-01-09 | 1 | 39786986 | [
"T cell therapies",
"T cells",
"T cell receptor",
"cancer cells",
"T cell-based therapies",
"additional effector populations",
"TME",
"Tumor Infiltrating Lymphocyte Therapy",
"CAR T",
"TCR T",
"powerful therapeutic approaches",
"cancer treatment",
"Chimeric Antigen",
"toxicity",
"resista... | [] | 0 | 10.1158/2326-6066.CIR-24-0857 | [
"Pherez-Farah",
"Boncompagni",
"Chudnovskiy",
"Pasqual"
] | [
"University of Padua, Padua, Italy.",
"University of Padua, Padua, 35128, Italy.",
"The Francis Crick Institute, United Kingdom.",
"University of Padua, Padua, PD, Italy."
] | [
"39786986"
] | [] | 10.227115 | 4.837266 |
39785827 | 53 | TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids. | Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model systems to identify and examine these ... | [
0.0028694644570350647,
-0.012481944635510445,
0.0498315803706646,
0.058056674897670746,
-0.023184191435575485,
-0.03239533677697182,
-0.009571895934641361,
0.031481437385082245,
-0.011459819972515106,
-0.017724841833114624,
-0.010497820563614368,
-0.0069504473358392715,
-0.00871812179684639,... | 2025-01-09 | 1 | 39785827 | [
"CAR T cells",
"cancer cells",
"target cell encounter",
"solid tumors",
"Multiple tumor microenvironmental factors",
"improved tumor control",
"CAR T-cell efficacy",
"CAR T-cell activity",
"enhanced CAR T-cell proliferation",
"CAR T-cell dysfunction",
"TBK1 inhibition",
"CAR T-cell therapy",
... | [] | 0 | 10.1158/2326-6066.CIR-23-1011 | [
"Sun",
"Maggs",
"Panda",
"Wright",
"Cicerchia",
"Jenney",
"Perricone",
"Mills",
"Cattaneo",
"Ventin",
"Chen",
"Rasmussen",
"Miranda",
"Revach",
"Fang",
"Fu",
"Bowling",
"Sharova",
"Lawless",
"Sorger",
"Bardeesy",
"Wang",
"Flaherty",
"Boland",
"Mehta",
"Sade-Feldman"... | [
"Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.\nBroad Institute of MIT and Harvard, Cambridge, Massachusetts.",
"Division of Gastrointestinal and Oncologic Surgery, Department of Surgery,... | [
"39785827"
] | [] | 9.545181 | 5.80253 |
39781479 | 54 | Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective. | Chimeric antigen receptor T (CAR-T) cell therapy, an emerging personalized immunotherapy for various haematologic malignancies, autoimmune diseases and other conditions, involves the modification of patients' T cells to express a chimeric antigen receptor that recognizes tumour or autoimmune cell antigens, allowing CAR... | [
-0.01488800160586834,
0.0025384880136698484,
0.05674168840050697,
0.04902445897459984,
-0.025828173384070396,
-0.027768632397055626,
0.019003111869096756,
-0.008146580308675766,
-0.014609199948608875,
0.011899248696863651,
-0.005893864203244448,
-0.04048198089003563,
-0.04295773804187775,
... | 2025-01-09 | 52 | 39781479 | [
"reported AKI incidence rates",
"cytokine release syndrome",
"other factors",
"tumour lysis syndrome",
"AKI",
"larger patient populations",
"specific CAR-T cell therapy",
"CAR-T cell therapy",
"higher rates",
"other medications",
"lower baseline glomerular filtration rate",
"other conditions",... | [
"acute kidney injury",
"autoimmunity",
"chimeric antigen receptor T-cell therapy",
"nephrotoxicity",
"onconephrology"
] | 0 | 10.1093/ckj/sfae359
10.1016/j.currproblcancer.2021.100826
10.1016/S0140-6736(23)01126-1
10.1038/s41591-022-02017-5
10.1056/NEJMoa2308917
10.1056/NEJMoa1707447
10.1177/2040620719841581
10.1056/NEJMoa2024850
10.1016/S0140-6736(21)00933-8
10.1007/s44228-023-00037-7
10.1016/j.bulcan.2022.08.014
10.1016/j.ekir.2021.02.013
1... | [
"Kanbay",
"Mizrak",
"Alper",
"Copur",
"Ortiz"
] | [
"Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.",
"Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.",
"Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.",
"Department of Medicine, Koc University School... | [
"39781479",
"35012754",
"37748491",
"36109639",
"38381673",
"29226797",
"31019670",
"33626253",
"34175021",
"37010812",
"36220698",
"34013119",
"30592986",
"27632680",
"38996858",
"34195558",
"38615919",
"31504777",
"36942605",
"35046131",
"29588419",
"31856973",
"1108723... | [] | 5.973433 | 4.174767 |
39781381 | 55 | Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer. | Resistance to the currently available treatment paradigms is one of the main factors that contributes to poor outcomes in patients with advanced cervical cancer. Novel targeted therapy approaches might enhance the patient's treatment outcome and are urgently needed for this malignancy. While chimeric-antigen receptor (... | [
0.020946966484189034,
0.0069586532190442085,
0.045278582721948624,
0.07020192593336105,
-0.046178001910448074,
-0.009822588413953781,
-0.005819587968289852,
0.02047358825802803,
-0.01337292231619358,
0.006124325096607208,
-0.0075326235964894295,
-0.03221335634589195,
-0.03566901385784149,
... | 2025-01-09 | 32 | 39781381 | [
"cervical cancer cells",
"cervical cancer cell lines",
"cervical cancer",
"advanced cervical cancer",
"primary human cervical cancer tissues",
"liquid cancers",
"adoptive immunotherapy displays",
"Anti-Mesothelin",
"Anti-Mesothelin CAR-NK cells",
"alpharetroviral SIN vectors",
"poor outcomes",
... | [
"CAR-NK cells",
"CAR-T cells",
"Mesothelin",
"cervical cancer",
"chemotherapy",
"chimeric antigen receptor (CAR)",
"immunotherapy"
] | 0 | 10.3389/fimmu.2024.1485461
10.1056/nejmoa1707447
10.1016/j.currproblcancer.2021.100826
10.1186/s13287-020-02128-1
10.1186/s13046-022-02327-z
10.3389/fimmu.2023.1105265
10.1007/s00404-018-4933-z
10.3390/biomedicines9040397
10.1006/mcbr.2000.0181
10.1128/MCB.20.8.2902-2906.2000
10.1074/jbc.M312372200
10.1186/s12967-024-0... | [
"Kutle",
"Polten",
"Stalp",
"Hachenberg",
"Todzey",
"Hass",
"Zimmermann",
"von der Ohe",
"von Kaisenberg",
"Neubert",
"Kamp",
"Schaudien",
"Seyda",
"Hillemanns",
"Klapdor",
"Morgan",
"Schambach"
] | [
"Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.",
"Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.",
"Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.\nDepartment of Gynecology and Obstetrics, Hannover Medical ... | [
"39781381",
"35012754",
"33494834",
"34980222",
"37180106",
"10683314",
"38637885",
"16226060",
"25103190",
"29329589",
"28346436",
"36387196",
"32920508",
"36139135",
"35091455",
"31980173",
"25340009",
"32762681",
"37370835",
"36045670",
"28724573",
"19719389",
"2911800... | [] | 11.026917 | 5.420137 |
39779871 | 56 | A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells. | Chimeric antigen receptor T cells (CAR T cells) with T stem (T | [
0.027601124718785286,
0.019044337794184685,
0.019252771511673927,
0.04633829742670059,
0.012506074272096157,
-0.03797897323966026,
-0.04034854471683502,
0.012780330143868923,
-0.007865662686526775,
-0.011793009005486965,
-0.028478745371103287,
-0.013855413533747196,
-0.03293266147375107,
-... | 2025-01-09 | 59 | 39779871 | [
"Chimeric antigen receptor T cells",
"CAR T cells",
"T",
"T stem"
] | [] | 0 | 10.1038/s41590-024-02042-1
10.1200/JCO.2014.56.2025
10.1056/NEJMoa1817226
10.1200/JCO.20.01342
10.1056/NEJMoa1407222
10.1182/blood-2017-06-786129
10.1182/bloodadvances.2019000525
10.1016/S0140-6736(21)01222-8
10.1182/bloodadvances.2020003959
10.1016/j.addr.2022.114421
10.1182/blood-2018-11-887067
10.1200/JCO.19.02104
1... | [
"Song",
"Tsahouridis",
"Stucchi",
"Walhart",
"Mendell",
"Hardy",
"Axtman",
"Guduru",
"Gilbert",
"Graves",
"Herring",
"Savoldo",
"Ma",
"Woodcock",
"Milner",
"Ivanova",
"Pearce",
"Xu",
"Dotti"
] | [
"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.",
"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.",
"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel... | [
"39779871",
"25154820",
"31042825",
"32701411",
"25317870",
"28935694",
"32045475",
"34097852",
"34100900",
"35809868",
"30782611",
"32401634",
"33512407",
"34666347",
"21984804",
"27111235",
"35110735",
"15931392",
"21926977",
"24782509",
"33035333",
"29138340",
"1952596... | [] | 8.126459 | 4.386631 |
39776916 | 57 | Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma. | Challenges remain in reducing antigen escape and tumor recurrence while CAR-T cell therapy has substantially improved outcomes in the treatment of multiple myeloma. T cell receptor fusion construct (TRuC)-T cells, which utilize intact T cell receptor (TCR)-CD3 complex to eliminate tumor cells in a non-major histocompat... | [
-0.01755348965525627,
-0.004990398418158293,
0.04542393237352371,
0.03036411479115486,
-0.054078441113233566,
-0.01152711734175682,
0.028408294543623924,
0.05217151343822479,
0.008159439079463482,
-0.0012048160424456,
-0.0034838055726140738,
-0.02474112994968891,
-0.0216851606965065,
0.010... | 2025-01-08 | 65 | 39776916 | [
"T cells",
"intact T cell receptor",
"T cell receptor fusion construct",
"tumor cells",
"TRuC)-T cells",
"B cell maturation antigen",
"dendritic cells",
"naïve T cells",
"BC-7×21 TRuC-T cells",
"CAR-T cell therapy",
"TCR)-CD3 complex",
"strong chemotaxis",
"stronger proliferation",
"the bi... | [
"B cell maturation antigen",
"C-C motif chemokine ligand 21",
"CD2 subset 1",
"T cell receptor fusion construct T cell",
"interleukin-7",
"multiple myeloma"
] | 0 | 10.3389/fimmu.2024.1502936
10.1016/S0753-3322(02)00194-4
10.1002/ijc.22718
10.1016/j.clml.2015.07.641
10.1073/pnas.86.24.10024
10.1158/0008-5472.CAN-11-3890
10.1016/j.cell.2018.03.038
10.1126/scitranslmed.3008226
10.1177/2515135520927164
10.1002/jha2.338
10.1056/NEJMoa2024850
10.1186/s13045-018-0681-6
10.1126/sciadv.ad... | [
"Li",
"Zheng",
"Liu",
"Zhang",
"Zhu",
"Xin",
"Zhao",
"Chen",
"Zheng",
"Zhao",
"Gao"
] | [
"Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.",
"Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.\nY... | [
"39776916",
"12199621",
"17405120",
"26361647",
"2784887",
"2513569",
"22315351",
"29706540",
"24553386",
"32524070",
"35844299",
"33626253",
"30572922",
"36791198",
"12507424",
"16087711",
"31064990",
"36875551",
"23344265",
"29641319",
"15827134",
"32055000",
"29812997"... | [] | 5.196897 | 6.090935 |
39776055 | 58 | Immunotherapy on ICU: a narrative review. | Patients with cancer account for 15% of all admissions to critical care and so an understanding of the pathophysiology and anticipated complications of specialist treatment is essential for the intensive care clinician. The development of chimeric antigen receptor T-cell therapy for haematological malignancies and immu... | [
0.012262379750609398,
0.033444926142692566,
0.04754381254315376,
0.03839550539851189,
-0.024479132145643234,
-0.002324148779734969,
0.043939244002103806,
0.011509526520967484,
0.017384061589837074,
0.027513358741998672,
-0.02100003883242607,
-0.03260082006454468,
-0.043277643620967865,
0.0... | 2025-01-08 | 1 | 39776055 | [
"immune effector cell toxicities",
"immune checkpoint inhibitors",
"toxicities",
"chimeric antigen receptor T-cell therapy",
"antigen receptor T-cell therapy",
"targeted drug therapies",
"treatment regimens",
"specialist treatment",
"antigen receptor T-cells",
"clinical trials",
"anticipated com... | [
"critical care",
"cytokine release syndrome",
"immune checkpoint inhibitors",
"receptors, chimeric antigen"
] | 0 | 10.1111/anae.16453 | [
"Carter",
"Wigmore"
] | [
"East of England School of Anaesthesia, Basildon, UK.",
"Department of Critical Care, The Royal Marsden Hospital, London, UK."
] | [
"39776055"
] | [] | 6.23885 | 3.934823 |
39775969 | 59 | Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications. | More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continue to emerge. Here, we summarize recent advances in mehanistic understanding and in targeted therapies for CALR-mutant MPN.
Structural insi... | [
0.0161287859082222,
0.03511332347989082,
0.062031883746385574,
0.041718799620866776,
-0.05140352249145508,
0.006487521808594465,
0.019506022334098816,
-0.010827022604644299,
-0.01470091100782156,
0.003122702008113265,
0.046933650970458984,
-0.059300296008586884,
-0.03176091983914375,
0.046... | 2025-01-08 | 54 | 39775969 | [
"mutant CALR",
"CALR",
"targeted therapies",
"mutant CALR-directed vaccines",
"mehanistic understanding",
"mechanistic understanding",
"CALR-mutant MPN",
"MPN",
"preclinical models",
"therapeutic targeting",
"chimeric antigen receptor",
"the mutant CALR-MPL complex",
"the mutant CALR C-termi... | [] | 0 | 10.1007/s11899-024-00749-4
10.1111/joim.13019
10.1016/S0140-6736(05)71142-9
10.1038/nature03546
10.1016/j.ccr.2005.03.023
10.1056/NEJMoa051113
10.1056/NEJMoa1311347
10.1056/NEJMoa1312542
10.1371/journal.pmed.0030270
10.1038/leu.2014.3
10.1182/blood-2016-10-695940
10.1128/MCB.25.20.8844-8853.2005
10.1042/BJ20081847
10.1... | [
"Faiz",
"Riedemann",
"Jutzi",
"Mullally"
] | [
"Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Institute of Medicine, Boston, MA, 02115, USA.",
"Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Institute of Medicine, Boston, MA, 02115, USA.",
"Division of Hematology, Department of M... | [
"39775969",
"31927786",
"15781101",
"15793561",
"15837627",
"15858187",
"24325356",
"24325359",
"16834459",
"24402162",
"28028029",
"19133842",
"26449662",
"26668133",
"26817954",
"26608331",
"26951227",
"26883579",
"33761144",
"29946189",
"29288169",
"30902807",
"3701990... | [] | 6.711076 | 7.163279 |
39775044 | 60 | Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. | Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H... | [
-0.004917621612548828,
0.024824917316436768,
0.04502437636256218,
0.0764184221625328,
-0.039734628051519394,
-0.04079257696866989,
-0.025243176147341728,
0.04982205852866173,
0.00982294138520956,
-0.03200913220643997,
0.005812573246657848,
0.003029304090887308,
-0.03744650259613991,
-0.011... | 2025-01-08 | 30 | 39775044 | [
"CAR T cell distribution",
"pediatric CNS tumors",
"repeated doses",
"ICV B7-H3 CAR T cells",
"B7-H3 CAR T cells",
"Diffuse intrinsic pontine glioma",
"DIPG",
"ICV",
"intra-patient dose-escalation regimens",
"protocol therapy",
"Arm C",
"Secondary objectives",
"B7-H3-targeting chimeric antig... | [] | 0 | 10.1038/s41591-024-03451-3
10.1093/neuonc/nox107
10.1007/s11940-019-0577-y
10.1182/blood-2017-02-769208
10.1056/NEJMoa1407222
10.1016/j.neo.2022.100870
10.1158/2159-8290.CD-22-0750
10.1200/JCO.23.02019
10.1038/s41591-021-01404-8
10.18632/oncotarget.27389
10.1093/neuonc/noaa278
10.1158/1078-0432.CCR-18-0432
10.1007/s110... | [
"Vitanza",
"Ronsley",
"Choe",
"Seidel",
"Huang",
"Rawlings-Rhea",
"Beam",
"Steinmetzer",
"Wilson",
"Brown",
"Beebe",
"Lindgren",
"Gustafson",
"Wein",
"Holtzclaw",
"Hoeppner",
"Goldstein",
"Browd",
"Hauptman",
"Lee",
"Ojemann",
"Crotty",
"Leary",
"Perez",
"Wright",
"... | [
"Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, WA, USA. nicholas.vitanza@seattlechildrens.org.\nDepartment of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA. nicholas.vitanza@seattlechildrens.org.\nSeattle Chi... | [
"39775044",
"28821206",
"31290035",
"28408462",
"25317870",
"36599192",
"36259971",
"39238483",
"38771986",
"34253928",
"31903167",
"33320196",
"30655315",
"23232807",
"31887631",
"30753824",
"31466914",
"34211478",
"32346608",
"33767145",
"16463390",
"37024595",
"2825132... | [] | 10.046144 | 6.926618 |
39774788 | 61 | Pre-treatment Pulmonary Function Testing Has Limited Utility In B-cell Lymphoma Treated with CD19 CAR T-cells. | Pulmonary function tests (PFT) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive significance of PFTs and pulmonary comorbidity classifications, per the Hematopoietic Ce... | [
0.01015382632613182,
-0.011318916454911232,
0.0547717809677124,
0.04041485860943794,
0.03442654386162758,
-0.012509062886238098,
-0.029716072604060173,
-0.0017679935554042459,
0.023589950054883957,
0.002635547425597906,
-0.04868324473500252,
0.011224958114326,
-0.03304848074913025,
0.00766... | 2025-01-08 | 1 | 39774788 | [
"Pulmonary comorbidity measures",
"pulmonary comorbidity level",
"hematopoietic cell transplantation",
"Pre-therapy PFT",
"Pulmonary function tests",
"Categorical FEV1",
"reduced PFS",
"multivariable Cox regression",
"therapy efficacy",
"FEV1",
"continuous measure",
"overall survival",
"PFS"... | [] | 0 | 10.1182/bloodadvances.2024014488 | [
"Sdayoor",
"Shouval",
"Fried",
"Marcus",
"Danylesko",
"Yerushalmi",
"Shem-Tov",
"Itzhaki",
"Jacoby",
"Kedmi",
"Nagler",
"Shimoni",
"Segel",
"Avigdor"
] | [
"Chaim Sheba Medical Center, Ramat Gan, Israel.",
"Memorial Sloan Kettering Cancer Center, New York, New York, United States.",
"Chaim Sheba Medical Center, Ramat Gan, Israel.",
"Chaim Sheba Medical Center, Ramat Gan, Israel.",
"Chaim Sheba Medical Center, Ramat Gan, Israel.",
"Chaim Sheba Medical Center.... | [
"39774788"
] | [] | 6.137629 | 5.248068 |
39769449 | 62 | Current Non-Viral-Based Strategies to Manufacture CAR-T Cells. | The successful application of CAR-T cells in the treatment of hematologic malignancies has fundamentally changed cancer therapy. With increasing numbers of registered CAR-T cell clinical trials, efforts are being made to streamline and reduce the costs of CAR-T cell manufacturing while improving their safety. To date, ... | [
0.005442037247121334,
0.01437563356012106,
0.04023773968219757,
0.026879744604229927,
-0.04136065021157265,
-0.028306780382990837,
0.011849078349769115,
0.016691643744707108,
0.00550052197650075,
-0.026482045650482178,
0.009123673662543297,
-0.014726544730365276,
-0.014001329429447651,
-0.... | 2025-01-08 | 169 | 39769449 | [
"different non-viral gene transfer methods",
"gene transfer",
"high gene transfer rates",
"CAR",
"CAR-T cell manufacturing",
"genomic integration methods",
"CAR-T cell production",
"targeted integration",
"registered CAR-T cell clinical trials",
"CAR-T cells",
"potential malignant transformation... | [
"CAR-T cells",
"CRISPR",
"gene transfer",
"non-integrating",
"non-viral",
"piggybac",
"programmable endonuclease",
"sleeping beauty",
"transient",
"transposase"
] | 0 | 10.3390/ijms252413685
10.1053/j.seminhematol.2020.07.005
10.1038/s41434-021-00254-w
10.1200/EDBK_397912
10.1038/mt.2016.11
10.1186/s12967-022-03729-5
10.1126/science.1088547
10.1038/s41586-018-0178-z
10.3390/ijms25137333
10.1038/s41578-024-00725-7
10.1016/j.gendis.2017.04.001
10.1093/nar/gks643
10.1038/mt.2010.47
10.10... | [
"Gehrke",
"Gonçalves",
"Andrae",
"Rasko",
"Ho",
"Einsele",
"Hudecek",
"Friedel"
] | [
"Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.",
"Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.",
"Medizinische Klinik und Polikli... | [
"39769449",
"32892841",
"33846552",
"37433102",
"26755332",
"36348415",
"14564000",
"29849141",
"39000440",
"28944281",
"22753106",
"20372108",
"30374197",
"36045296",
"14724672",
"9862961",
"11237011",
"2543105",
"17984973",
"25605795",
"27491640",
"29858090",
"17440442"... | [] | 9.076534 | 2.917784 |
39769267 | 63 | Genetically Engineered T Cells and Recombinant Antibodies to Target Intracellular Neoantigens: Current Status and Future Directions. | Recombinant antibodies and, more recently, T cell receptor (TCR)-engineered T cell therapies represent two immunological strategies that have come to the forefront of clinical interest for targeting intracellular neoantigens in benign and malignant diseases. T cell-based therapies targeting neoantigens use T cells expr... | [
0.01663902960717678,
0.010378068313002586,
0.05691162124276161,
0.044423818588256836,
-0.024611659348011017,
-0.0014486645814031363,
0.01997138373553753,
0.032777637243270874,
0.0009041714365594089,
0.01182815432548523,
-0.0050753019750118256,
-0.03709946200251579,
-0.0055529773235321045,
... | 2025-01-08 | 101 | 39769267 | [
"T cell receptor",
"recombinant T cells",
"T cell",
"T cells",
"different recombinant T cells",
"TCR)-engineered T cell therapies",
"intracellular neoantigens",
"TCR",
"neoantigens",
"T cell-based therapies",
"the synthetic T cell receptor",
"antigen receptor",
"immune checkpoint blocking an... | [
"CD3 × TCR-like antibody)",
"CRISPR/Cas9-based genome editing",
"STARs",
"T CARs",
"TCR-CARs",
"TCR-like CARs",
"TCR-like antibodies",
"bispecific antibody (CD3 × TCR",
"checkpoint blocking antibodies",
"intrabodies",
"neoantigens",
"therapeutic mRNA"
] | 0 | 10.3390/ijms252413504
10.20517/2394-4722.2017.41
10.1186/s13045-019-0788-4
10.3390/antib11030049
10.1158/1078-0432.CCR-22-0028
10.3389/fimmu.2023.1121030
10.1016/j.ijbiomac.2022.03.113
10.3389/fonc.2022.836821
10.1038/s41392-022-01270-x
10.1038/s41598-024-58094-8
10.1016/j.intimp.2024.112730
10.1016/j.ejphar.2024.17672... | [
"Waaga-Gasser",
"Böldicke"
] | [
"Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.",
"Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany."
] | [
"39769267",
"31521180",
"35892709",
"36255733",
"36949949",
"35339499",
"35311072",
"36604431",
"38548901",
"39083927",
"38866361",
"34140957",
"33013822",
"37280206",
"31591590",
"35309357",
"33654227",
"36923303",
"33762437",
"29312332",
"29321773",
"31907209",
"3443939... | [] | 9.372404 | 4.370181 |
39768494 | 64 | Emergencies in Hematology: Why, When and How I Treat? | Hematological emergencies are critical medical conditions that require immediate attention due to their rapid progression and life-threatening nature. As various examples, hypercalcemia, often associated with cancers such as multiple myeloma, can lead to severe neurological and cardiac dysfunction. Hyperleukocytosis, c... | [
-0.00677148113027215,
0.04398293048143387,
0.07127632200717926,
0.07081528753042221,
-0.025979435071349144,
-0.010125525295734406,
0.04059430956840515,
0.006990473717451096,
-0.012978192418813705,
-0.003515407210215926,
0.031235257163643837,
-0.012909036129713058,
-0.07916005700826645,
-0.... | 2025-01-08 | 130 | 39768494 | [
"hematological conditions",
"cancer cells",
"chimeric antigen receptor T cells",
"sickle cell disease",
"acute myeloid leukemias",
"critical medical conditions",
"acute promyelocytic leukemia",
"Sickle cell crisis",
"hematological malignancies",
"cytokine release syndrome",
"acute kidney injury"... | [
"CAR-T complications",
"DIC",
"PTT",
"TLS",
"emergencies",
"hypercalcemia",
"hyperleukocytosis",
"septic shock",
"sickle crisis",
"transfusion reactions"
] | 0 | 10.3390/jcm13247572
10.1055/a-1049-0647
10.1001/jama.2022.18331
10.7861/clinmed.2023-0227
10.1007/s12020-017-1353-y
10.7759/cureus.35783
10.1002/cam4.3594
10.1002/jbmr.2022
10.4065/78.1.21
10.1359/JBMR.040314
10.1001/archsurg.1980.01380060012004
10.1359/jbmr.2003.18.3.579
10.1159/000106100
10.3322/caac.21727
10.2147/CI... | [
"Duminuco",
"Del Fabro",
"De Luca",
"Leotta",
"Limoli",
"Longo",
"Nardo",
"Santuccio",
"Petronaci",
"Stanzione",
"Di Raimondo",
"Palumbo"
] | [
"Hematology Unit with BMT, A.O.U. Policlinico \"G.Rodolico-San Marco\", 95123 Catania, Italy.",
"Faculty of Medicine and Surgery, \"Kore\" University of Enna, 94100 Enna, Italy.",
"Hematology Unit with BMT, A.O.U. Policlinico \"G.Rodolico-San Marco\", 95123 Catania, Italy.",
"Hematology Unit with BMT, A.O.U. ... | [
"39768494",
"31826272",
"36282253",
"37775175",
"28613465",
"28667379",
"37025710",
"33145966",
"23787729",
"12528874",
"15176993",
"7387355",
"12619944",
"17641550",
"35653456",
"22977302",
"33080779",
"29149122",
"34285568",
"36983189",
"27018197",
"11264180",
"17880610... | [] | 6.091089 | 4.105611 |
39767716 | 65 | Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma. | CD19-targeting chimeric antigen receptor (CAR) T-cells have changed the treatment paradigm of patients with large B-cell lymphoma (LBCL). Three CAR T-cells were approved by the Food and Drug Administration (FDA) for patients with relapsed and/or refractory (R/R) LBCL in the third-line setting: tisagenlecleucel (tisa-ce... | [
0.009968819096684456,
0.004878293722867966,
0.052099812775850296,
0.06117119640111923,
-0.0013097717892378569,
0.0030879690311849117,
-0.009059255011379719,
-0.006118332501500845,
0.04855857789516449,
-0.015389818698167801,
0.0035836813040077686,
-0.05898824334144592,
-0.06907833367586136,
... | 2025-01-08 | 76 | 39767716 | [
"patients",
"CAR T-cells",
"CD19-targeting CAR T-cells",
"cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome",
"large B-cell lymphoma",
"lisocabtagene maraleucel",
"LBCL",
"R/R disease",
"Three CAR T-cells",
"R/R LBCL",
"BsAb",
"second-line treatments",
"ter... | [
"CD19-targeting CAR T-cells",
"axicabtagene ciloleucel",
"large B-cell lymphoma",
"lisocabtagene maraleucel",
"tisagenlecleucel"
] | 0 | 10.3390/biomedicines12122810
10.1056/NEJMoa011795
10.1182/blood-2010-03-276246
10.1016/S0140-6736(11)61040-4
10.3322/caac.21763
10.1016/S1470-2045(17)30444-8
10.3390/jpm14070666
10.1056/NEJMoa1707447
10.1056/NEJMoa1804980
10.1016/S0140-6736(20)31366-0
10.1056/NEJMoa2116133
10.1016/S0140-6736(22)00662-6
10.1200/JCO.22.0... | [
"Saleh",
"Khalife",
"Arbab",
"Khoury",
"Chahine",
"Ibrahim",
"Tikriti",
"Masri",
"Hachem",
"Le Cesne"
] | [
"International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.",
"Department of Head and Neck, Gustave Roussy Cancer Campus, 94800 Villejuif, France.",
"Department of Biopathology, Gustave Roussy Cancer Campus, 94800 Villejuif, France.",
"International Department, Gustave Roussy Cancer Camp... | [
"39767716",
"11807147",
"20548096",
"22118442",
"36633525",
"28668386",
"39063920",
"29226797",
"30501490",
"32888407",
"34891224",
"35717989",
"36548927",
"36507690",
"30181329",
"25621840",
"21830940",
"24986688",
"28652918",
"11753365",
"20647327",
"24273543",
"3009743... | [] | 6.096278 | 5.216356 |
39766419 | 66 | CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities. | The advent of chimeric antigen receptor (CAR)-T cells has recently changed the prognosis of relapsing/refractory diffuse large B-cell lymphomas, showing response rates as high as 60 to 80%. Common toxicities reported in the pivotal clinical trials include the cytokine release syndrome (CRS) and the Immune effector Cell... | [
0.015434326604008675,
0.043981000781059265,
0.05094693601131439,
0.03724271059036255,
-0.03976957127451897,
-0.02661169320344925,
0.027385685592889786,
0.012281443923711777,
-0.019714051857590675,
-0.010369226336479187,
-0.015866851434111595,
-0.00896351970732212,
-0.07161709666252136,
0.0... | 2025-01-08 | 137 | 39766419 | [
"CAR)-T cells",
"myeloid cell activation",
"solid CNS tumours",
"solid tumours",
"focal neurological deficits",
"attention deficits",
"patients",
"systemic B-cell malignancies",
"local inflammation",
"chimeric antigen receptor",
"large B-cell lymphomas",
"several CNS cancers",
"available dat... | [
"CAR-T cells",
"CNS tumours",
"ICANS",
"TIAN",
"neurotoxicity"
] | 0 | 10.3390/brainsci14121220
10.1056/NEJMoa1707447
10.1056/NEJMoa1709866
10.1056/NEJMoa1709919
10.1056/NEJMoa1804980
10.1016/S1470-2045(18)30864-7
10.1016/S0140-6736(20)31366-0
10.1056/NEJMoa1914347
10.1016/S0140-6736(21)00933-8
10.1056/NEJMoa2024850
10.1038/s41591-021-01622-0
10.1056/NEJMra1706169
10.1038/nature22395
10.1... | [
"Palazzo",
"Pieri",
"Berzero",
"Filippi"
] | [
"Neurology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.\nFaculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.",
"Neurology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.\nFaculty of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.",
"Neurology Unit, I... | [
"39766419",
"29226797",
"29385370",
"29385376",
"30501490",
"30518502",
"32888407",
"32242358",
"34175021",
"33626253",
"34921238",
"29972754",
"28541315",
"34002066",
"29808007",
"30592986",
"32084260",
"32007196",
"36721024",
"32735779",
"36813894",
"33025047",
"3695194... | [] | 6.14942 | 4.231815 |
39764559 | 67 | Loading of CAR-T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism. | Therapies against hematological malignancies using chimeric antigen receptors (CAR)-T cells have shown great potential; however, therapeutic success in solid tumors has been constrained due to limited tumor trafficking and infiltration, as well as the scarcity of cancer-specific solid tumor antigens. Therefore, the enr... | [
0.020637188106775284,
-0.014680649153888226,
-0.014862876385450363,
0.04380277544260025,
-0.039474885910749435,
-0.042253848165273666,
-0.007095457520335913,
-0.001364565803669393,
0.004003295674920082,
-0.02927018515765667,
-0.015569005161523819,
0.012345868162810802,
-0.05931483581662178,
... | 2025-01-07 | 79 | 39764559 | [
"CAR)-T cells",
"melanoma cells",
"solid tumors",
"limited tumor trafficking",
"tumor",
"reduced systemic adverse side effects",
"human CAR-T cells",
"cancer-specific solid tumor antigens",
"tumor-antigen specific CAR-T cells",
"chimeric antigen receptors",
"superparamagnetic iron oxide nanopart... | [
"CAR‐T cell",
"adoptive T cell therapy",
"cancer",
"magnetic cell targeting",
"pyroptosis",
"superparamagnetic iron oxide nanoparticles (SPIONs)"
] | 0 | 10.1002/mco2.70039 | [
"Pfister",
"Carnell",
"Löffler",
"Boosz",
"Schaft",
"Dörrie",
"Stein",
"Lenz",
"Spiecker",
"Huber",
"Haddadin",
"Berking",
"Alexiou",
"Janko"
] | [
"Department of Otorhinolaryngology Head and Neck Surgery Section of Experimental Oncology and Nanomedicine (SEON) Else Kröner-Fresenius-Stiftung Professorship Universitätsklinikum Erlangen Erlangen Germany.",
"Department of Otorhinolaryngology Head and Neck Surgery Section of Experimental Oncology and Nanomedicin... | [
"39764559",
"38572751",
"33167514",
"25675873",
"28344995",
"35658469",
"36765623",
"33824268",
"23550147",
"22262649",
"27626062",
"27207799",
"33972771",
"23242161",
"20926399",
"21279377",
"28769560",
"27698936",
"18182491",
"25652717",
"35101971",
"34439296",
"3174961... | [] | 9.707909 | 4.57403 |
39763668 | 68 | Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma. | Clinical studies have demonstrated the high efficacy of using chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) and orphan G protein-coupled receptor, class C group 5 member D (GPRC5D) to treat relapsed or refractory multiple myeloma (RRMM). In this study, we compared the efficacy and s... | [
0.034828707575798035,
0.026804447174072266,
0.05487716570496559,
0.036682337522506714,
-0.018902134150266647,
-0.014011969789862633,
0.004698094911873341,
0.0070791542530059814,
0.035389672964811325,
-0.011030309833586216,
0.002341425744816661,
-0.032145824283361435,
-0.036365266889333725,
... | 2025-01-07 | 49 | 39763668 | [
"%",
"67.9%-84.7%",
"BCMA",
"BCMA CAR-T treatment",
"MRD negativity rate",
"GPRC5D",
"BCMA CAR-T",
"GPRC5D CAR-T",
"GPRC5D CAR T-cell therapy",
"RRMM patients",
"relapse rate",
"BCMA CAR-T and GPRC5D CAR-T",
"eligible clinical trials",
"chimeric antigen receptor",
"overall response rate"... | [
"B-cell maturation antigen",
"G protein-coupled receptor",
"car-T",
"class C group 5 member D",
"relapsed or refractory multiple myeloma"
] | 0 | 10.3389/fimmu.2024.1466443
10.1016/S1470-2045(14)70442-5
10.1038/s41408-020-00359-2
10.3390/jpm11050334
10.1016/S0140-6736(14)60493-1
10.1200/JCO.2013.48.7934
10.1016/S0140-6736(16)31594-X
10.1056/NEJMoa1402551
10.1038/leu.2017.138
10.1182/blood-2015-07-635383
10.3324/haematol.2020.276402
10.1038/s41375-020-0930-x
10.1... | [
"Yang",
"Wang",
"Yuan",
"Yang",
"Chen",
"Cheng",
"Liu",
"Tang",
"Xu",
"Wang",
"He",
"Liu",
"Li"
] | [
"Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.",
"Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.\nAcademy of Medical En... | [
"39763668",
"25439696",
"32989217",
"33922567",
"25540889",
"24419113",
"28017406",
"25184863",
"37658559",
"28620163",
"26679866",
"33792221",
"32572190",
"29812997",
"37545132",
"33596362",
"29385376",
"29226797",
"29385370",
"30918115",
"32040549",
"36170501",
"2751115... | [] | 5.109542 | 5.783523 |
39763064 | 69 | Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR. | Paediatric sarcomas, including rhabdomyosarcoma, Ewing sarcoma and osteosarcoma, represent a group of malignancies that significantly contribute to cancer-related morbidity and mortality in children and young adults. These cancers share common challenges, including high rates of metastasis, recurrence or treatment resi... | [
0.029741927981376648,
0.03454483300447464,
0.030598783865571022,
0.02126356214284897,
-0.019978277385234833,
-0.014656749553978443,
-0.00020522973500192165,
0.019718965515494347,
0.02613411284983158,
-0.011454814113676548,
0.009042087011039257,
-0.07919154316186905,
-0.05610152706503868,
0... | 2025-01-07 | 89 | 39763064 | [
"NK cells",
"unmodified NK cells",
"several paediatric sarcoma cell lines",
"sarcoma cell lines",
"Paediatric sarcomas",
"paediatric sarcomas",
"NK",
"multiple paediatric sarcomas",
"various paediatric sarcomas",
"CAR expression",
"EphA2-CAR NK cells",
"CAR-NK cells",
"solid tumours",
"CAR... | [
"CAR‐NK cell therapy",
"EphA2",
"Ewing sarcoma",
"immunotherapy",
"osteosarcoma",
"paediatric sarcomas",
"rhabdomyosarcoma"
] | 0 | 10.1002/ctm2.70140 | [
"Lam",
"Omer",
"Wong",
"Tu",
"Alim",
"Rossi",
"Victorova",
"Tompkins",
"Lin",
"Mehdi",
"Choo",
"Elliott",
"Coleborn",
"Sun",
"Mercer",
"Vittorio",
"Dobson",
"McLellan",
"Brooks",
"Tuong",
"Cheetham",
"Nicholls",
"Souza-Fonseca-Guimaraes"
] | [
"Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Queensland, Australia.",
"Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Queensland, Australia.\nQueensland Children's Hospital, Brisbane, Queensland, Australia.",
"Frazer Institute, Faculty... | [
"39763064",
"33322371",
"33196879",
"26848927",
"34131316",
"33497548",
"31921698",
"38693888",
"36379852",
"20542985",
"26363055",
"31741777",
"30556159",
"33859303",
"28507811",
"34804076",
"32934330",
"38444031",
"36853475",
"32023374",
"30962163",
"34159300",
"3679270... | [] | 11.015425 | 6.043037 |
39762445 | 70 | The epitranscriptional factor PCIF1 orchestrates CD8 | T cell-based immunotherapies have revolutionized cancer treatment, yet durable responses remain elusive. Here we show that PCIF1, an RNA N | [
-0.00985148549079895,
0.02620866894721985,
0.0757913812994957,
0.024164021015167236,
-0.009857294149696827,
-0.030135322362184525,
0.02428019419312477,
0.041892047971487045,
0.0217011496424675,
-0.004995446652173996,
-0.009224150329828262,
0.02451254054903984,
-0.012395678088068962,
-0.014... | 2025-01-07 | 58 | 39762445 | [
"cancer treatment",
"durable responses",
"RNA N",
"PCIF1",
"T cell-based immunotherapies",
"an RNA N",
"that PCIF1",
"we"
] | [] | 0 | 10.1038/s41590-024-02047-w
10.1038/s41590-021-00964-8
10.1016/j.immuni.2015.01.006
10.1158/2159-8290.CD-23-0007
10.1038/s41586-019-1805-z
10.1038/s41586-019-0979-8
10.1038/nrm.2016.132
10.1038/s41576-020-00295-8
10.1016/j.cell.2022.02.007
10.1038/257251a0
10.1016/S0021-9258(17)34652-5
10.1038/nature21022
10.1016/j.molc... | [
"Xiang",
"Zhang",
"Li",
"Zhang",
"Liu",
"Gao",
"Wang",
"Xiao",
"Sun",
"He",
"Shi",
"Fan",
"Xing",
"Xu",
"Yao",
"Chen",
"Zhu",
"Yi",
"Zhang"
] | [
"Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.\nTaikang Ce... | [
"39762445",
"34282330",
"25680272",
"37548590",
"31802004",
"30814730",
"27808276",
"33188361",
"35245480",
"1161029",
"670176",
"28002401",
"30197295",
"30467178",
"30487554",
"31279659",
"31279658",
"34545078",
"34266951",
"36689652",
"35597784",
"36514940",
"37643007",... | [] | 9.544352 | 4.553657 |
39762075 | 71 | New developments in immunotherapy for SCLC. | Small cell lung cancer (SCLC) is an aggressive form of neuroendocrine neoplasm known for its striking initial response to treatment, followed by fast relapse and refractoriness in response to additional lines of therapy. New advances in immunotherapy are paving the way for more effective treatment strategies and have p... | [
0.0048174867406487465,
0.006379592232406139,
0.059145379811525345,
0.03343622013926506,
-0.005577671807259321,
-0.008215961046516895,
0.006904269102960825,
0.003392512211576104,
-0.00513646611943841,
0.005577671807259321,
-0.013939707539975643,
-0.06830337643623352,
-0.025065239518880844,
... | 2025-01-07 | 43 | 39762075 | [
"bispecific T cell engagers",
"chimeric antigen receptor T cells",
"Small cell lung cancer",
"early clinical trial data",
"CAR-T cells",
"treatment",
"neuroendocrine neoplasm",
"response",
"fast relapse",
"DLL3",
"actionable mutations",
"additional lines",
"the first CAR-T cell trials",
"i... | [
"Bispecific T cell engager - BiTE",
"Immunotherapy",
"Lung Cancer"
] | 0 | 10.1136/jitc-2024-009667
10.1016/j.lungcan.2021.04.013
10.1016/S1470-2045(20)30068-1
10.1038/s41572-020-00235-0
10.1016/j.celrep.2016.06.081
10.1016/j.ccell.2020.12.014
10.1016/j.cell.2023.12.004
10.1001/jamaoncol.2023.4025
10.1101/gad.349359.122
10.1053/bbmt.2002.v8.pm12064365
10.1056/NEJMoa1809064
10.1016/S0140-6736(... | [
"Dolkar",
"Gates",
"Hao",
"Munker"
] | [
"Hospital Medicine, University of Kentucky, Lexington, Kentucky, USA.",
"Hematology - Oncology, University of Kentucky, Lexington, Kentucky, USA.",
"Medical Oncollogy, University of Kentucky, Lexington, Kentucky, USA.",
"University of Kentucky, Lexington, Kentucky, USA rmunker@uky.edu."
] | [
"39762075",
"32224306",
"33446664",
"27452466",
"33482121",
"38181741",
"37824137",
"35318269",
"12064365",
"30280641",
"31590988",
"34656433",
"37976444",
"33707236",
"39268857",
"30874360",
"37930513",
"39309421",
"37731022",
"35046060",
"36167468",
"32733795",
"3502219... | [] | 7.301825 | 6.355901 |
39762074 | 72 | XCL1-secreting CEA CAR-T cells enhance endogenous CD8 | Therapeutic efficacy of carcinoembryonic antigen (CEA)-specific chimeric antigen receptor (CAR) T cells against colorectal cancer (CRC) remains limited due to the unique characteristics and distinct microenvironments of tumor tissues. We modified CEA-specific CAR-T cells, aiming to stimulate endogenous CD8
In a convent... | [
0.04604463651776314,
0.012994615361094475,
0.059062253683805466,
0.05575035139918327,
-0.041628770530223846,
0.008147508837282658,
0.004545240662992001,
0.011269666254520416,
0.014397574588656425,
-0.014374574646353722,
-0.01003345288336277,
-0.03256703540682793,
-0.029209136962890625,
0.0... | 2025-01-07 | 40 | 39762074 | [
"T cells",
"CRC cells",
"CEA expression",
"CEA",
"CAR",
"CEA-negative CT26 cells",
"reg-CAR T cells",
"CEA-specific CAR-T cells",
"tumor tissues",
"CEA)-specific chimeric antigen receptor",
"similar positive proportions",
"co-culture system",
"CEA-positive tumors",
"endogenous CD8",
"the... | [
"Chimeric antigen receptor - CAR",
"Colorectal Cancer",
"Dendritic",
"Immunotherapy",
"T cell"
] | 0 | 10.1136/jitc-2024-010581
10.1001/jama.2021.0106
10.1016/j.eclinm.2021.101134
10.1136/jitc-2020-001097
10.1016/j.ymthe.2017.03.010
10.1186/s13045-020-00890-6
10.3389/fimmu.2022.841425
10.1186/s12943-023-01723-z
10.1038/nbt.4086
10.1038/mt.2013.262
10.1016/j.ccell.2022.04.006
10.1016/j.cell.2020.08.053
10.1038/s41586-023... | [
"Li",
"Wang",
"Chen",
"Wu",
"Zhang",
"Xiao",
"Zhao",
"Wang",
"Zhao",
"Ran",
"Qu"
] | [
"Immunology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.",
"Immunology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese ... | [
"39762074",
"33591350",
"32843493",
"28366766",
"32423475",
"35401510",
"36717905",
"29505028",
"24213558",
"35487216",
"33064988",
"30550719",
"29328785",
"35303421",
"19285437",
"31467405",
"27424807",
"26755602",
"28486109",
"34597124",
"34534439",
"30635237",
"3077825... | [] | 9.384993 | 5.857348 |
39761676 | 73 | mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells. | Chimeric antigen receptor T-cell (CAR-T) therapy has shown transformative potential in treating malignant tumours, with increasing global approval of CAR-T products. However, high-production costs and risks associated with viral vector-based CAR-T cells-such as insertional mutagenesis and secondary tumour formation-rem... | [
0.015830691903829575,
-0.007984576746821404,
0.01926913671195507,
0.020688360556960106,
-0.024346036836504936,
-0.03263061121106148,
0.017434531822800636,
0.007424964103847742,
0.00029549136525020003,
-0.03726905211806297,
-0.005451896693557501,
-0.0010766774648800492,
-0.08312267810106277,
... | 2025-01-07 | 1 | 39761676 | [
"tumour cell killing",
"Raji cells",
"high CAR expression",
"marked tumour regression",
"leukaemic cells",
"malignant tumours",
"CAR",
"strong anti-tumour efficacy",
"treated mice",
"mRNA-LNP CAR-T cells",
"CAR-T safety",
"increased cytokine secretion",
"Therapeutic efficacy",
"transformat... | [
"CAR‐T cells",
"Leukaemia eradication",
"mRNA‐LNP",
"non‐viral transfection"
] | 0 | 10.1111/bjh.19988 | [
"Chen",
"Ren",
"Li",
"Shu",
"Wu",
"Huang",
"Wang",
"Hu",
"Mei"
] | [
"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.\nHubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China.\nHubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Hua... | [
"39761676"
] | [] | 9.895608 | 3.348808 |
39759518 | 74 | Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy. | Although CAR-T cell therapy has limited efficacy against solid tumors, it has been hypothesized that prior treatment with Image-Guided Radiation Therapy (IGRT) would increase CAR-T cell tumor infiltration, leading to improved antigen specific expansion of CAR-T cells.
To test this hypothesis in a metastatic triple nega... | [
0.044950708746910095,
-0.021699918434023857,
0.030918998643755913,
0.04187357798218727,
-0.0736541748046875,
-0.023780057206749916,
-0.0051234206184744835,
0.01481945626437664,
-0.026290996000170708,
-0.019767479971051216,
0.012739316560328007,
0.00010433392890263349,
-0.02769416570663452,
... | 2025-01-06 | 50 | 39759518 | [
"CAR-T cell infiltration",
"CAR-T cell tumor infiltration",
"CAR-T cells",
"solid tumors",
"The anti-CEA scFab CAR-T cells",
"CAR-T cell therapy",
"scFab CAR-T therapy",
"improved antigen specific expansion",
"limited efficacy",
"overall efficacy",
"CEA",
"prior treatment",
"a metastatic tri... | [
"carcinoembryonic antigen",
"cell immunotherapy",
"chimeric antigen receptor T cells",
"image-guided radiation therapy",
"triple-negative breast cancer"
] | 0 | 10.3389/fimmu.2024.1499471
10.1016/j.compbiomed.2022.105508
10.18632/oncotarget.12284
10.3390/molecules29071646
10.1517/13543784.2012.681045
10.1001/jamaoncol.2018.7147
10.1186/s40425-018-0460-5
10.1126/science.ade0156
10.1186/s13287-020-02128-1
10.3892/ol.2023.13867
10.1186/s12943-023-01775-1
10.3389/pore.2022.1610378... | [
"Aniogo",
"Kujawski",
"Awuah",
"Cha",
"Espinosa",
"Hui",
"Ghimire",
"Yazaki",
"Brown",
"Wang",
"Shively"
] | [
"Department of Immunology and Theranostics, City of Hope, Duarte, CA, United States.",
"Department of Immunology and Theranostics, City of Hope, Duarte, CA, United States.",
"T-Cell Therapeutic Laboratory, City of Hope, Duarte, CA, United States.",
"Department of Immunology and Theranostics, City of Hope, Dua... | [
"39759518",
"35447458",
"27765921",
"38611925",
"22500582",
"30973611",
"30514386",
"36520914",
"33494834",
"37274466",
"37173782",
"35832115",
"31221199",
"31294749",
"32822275",
"36239313",
"32381294",
"35741103",
"7914825",
"15316127",
"33796409",
"22750462",
"25635232... | [] | 9.601356 | 5.726479 |
39757684 | 75 | Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy. | Cancer is a significant health challenge worldwide, causing social and economic burdens. Despite advancements in medicine, it remains a leading cause of death and is projected to increase by 2040. While conventional treatments like surgery, radiation, and chemotherapy are effective, they often have severe side effects.... | [
0.005489378236234188,
0.008667130954563618,
0.07312928885221481,
0.08567643910646439,
-0.03717327490448952,
-0.026990419253706932,
0.012828056700527668,
0.01745130680501461,
0.01053398847579956,
0.0159414354711771,
-0.00012125059583922848,
-0.034223757684230804,
-0.04735612869262695,
0.000... | 2025-01-06 | 1 | 39757684 | [
"cancer cells",
"cancer treatment paradigms",
"severe side effects",
"conventional treatments",
"ongoing research",
"solid tumours",
"Cancer",
"CAR T-cell therapy",
"challenges",
"high costs",
"remarkable success",
"CAR T-cells",
"patients",
"renewed optimism",
"CAR T-cell (chimeric anti... | [
"CAR T-cell",
"Cancer",
"immunotherapy",
"malignancy",
"oncology.",
"side effects",
"treatment",
"tumour"
] | 0 | 10.2174/0113816128336391241107112957 | [
"Barjasteh",
"Saebi",
"Mahmoudi",
"Kheder",
"Hashemy",
"Forouzanfar",
"Esmaeili"
] | [
"Immunology Department, Mashhad University of Medical Sciences, Faculty of Medicine, Mashhad, Iran.",
"Immunology Department, Mashhad University of Medical Sciences, Faculty of Medicine, Mashhad, Iran.",
"Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.\nImmunology Department, ... | [
"39757684"
] | [] | 9.752551 | 3.954268 |
39757079 | 76 | Chimeric antigen receptor-T cells targeting AFP-GPC3 mediate increased antitumor efficacy in hepatocellular carcinoma. | As a novel immunotherapy, chimeric antigen receptor T (CAR-T) cell technology is successful in treating hematologic malignancies, and exhibits potential benefits in partial solid tumors. Therapies targeting one antigen have some weaknesses, and dual-targeted CAR-T cells may be a better option. Alpha-fetoprotein (AFP) a... | [
-0.013530995696783066,
-0.02156430296599865,
0.07085908204317093,
0.0667559802532196,
-0.027937931939959526,
-0.027269450947642326,
-0.015720849856734276,
0.02233651466667652,
0.019420551136136055,
-0.019662586972117424,
0.011150969192385674,
-0.009133998304605484,
-0.05555314943194389,
-0... | 2025-01-06 | 1 | 39757079 | [
"AFP CAR",
"GPC3 CAR",
"HCC cells",
"Huh-7 cell",
"Huh-7 cells",
"AFP",
"effector cells",
"CAR",
"GPC3",
"chimeric antigen receptor T",
"AFP-GPC3 CAR constructs",
"human T lymphocytes",
"specific targeting antigen molecules",
"AFP-GPC3 CAR-T cells",
"AFP CAR-T",
"AFP CAR-T and GPC3 CAR... | [
"AFP",
"Chimeric antigen receptor T cell",
"GPC3",
"Hepatocellular carcinoma",
"Immunotherapy"
] | 0 | 10.1016/j.ajg.2024.12.002 | [
"Li",
"Chen",
"Huang",
"Cen",
"Zhao",
"Fan",
"He"
] | [
"Embryo Formation Teaching and Research Section, Guangxi University of Chinese Medicine, No.13 Wuhe Avenue, Nanning 530200, Guangxi, China.",
"Embryo Formation Teaching and Research Section, Guangxi University of Chinese Medicine, No.13 Wuhe Avenue, Nanning 530200, Guangxi, China.",
"Embryo Formation Teaching a... | [
"39757079"
] | [] | 9.159325 | 5.888499 |
39755643 | 77 | From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy. | In the past decades, Chimeric Antigen Receptor (CAR)-T cell therapy has achieved remarkable success, leading to the approval of six therapeutic products for haematological malignancies. Recently, the therapeutic potential of this therapy has also been demonstrated in non-tumoral diseases. Currently, the manufacturing p... | [
0.01614723913371563,
0.012987266294658184,
0.028126005083322525,
0.046525564044713974,
-0.021088900044560432,
-0.031442854553461075,
0.013278611935675144,
0.01083019282668829,
-0.0015393664361909032,
-0.007300435099750757,
0.019318418577313423,
-0.010964659042656422,
-0.023576539009809494,
... | 2025-01-05 | 137 | 39755643 | [
"vivo T cell reprogramming",
"T cells",
"ex vivo cell manipulation",
"CAR)-T cell therapy",
"therapeutic cell populations",
"other immune cell types",
"ex vivo manufacturing process",
"ex vivo",
"vivo reprogramming",
"vivo engineering",
"produced CAR-T cells",
"manufactured CAR-T cells",
"CA... | [
"CAR T cell",
"Manufacturing",
"T cell engineering"
] | 0 | 10.1186/s12967-024-06052-3 | [
"Pinto",
"Lione",
"Compagnone",
"Paccagnella",
"Salvatori",
"Greco",
"Frezza",
"Marra",
"Aurisicchio",
"Roscilli",
"Conforti"
] | [
"Evvivax Biotech, Via Castel Romano 100, 00128, Rome, Italy.\nDepartment of Clinical Sciences and Translational Medicine, University of Rome \"Tor Vergata\", Via Montpellier 1, 00133, Rome, Italy.",
"Takis Biotech, Via Castel Romano 100, 00128, Rome, Italy.",
"Evvivax Biotech, Via Castel Romano 100, 00128, Rome... | [
"39755643",
"31707680",
"30936321",
"20555360",
"28180032",
"18453625",
"18354214",
"32397414",
"33833759",
"33795428",
"36123710",
"32739874",
"26700307",
"3122749",
"2784887",
"2513569",
"36094837",
"11123291",
"28187291",
"32616000",
"33888899",
"21217771",
"12974476",... | [] | 8.724868 | 3.100957 |
39755633 | 78 | Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer. | Breast cancer will overtake all other cancers in terms of diagnoses in 2024. Breast cancer counts highest among women in terms of cancer incidence and death rates. Innovative treatment approaches are desperately needed because treatment resistance brought on by current clinical drugs impedes therapeutic efficacy. The T... | [
0.0020095580257475376,
-0.002213285770267248,
0.0634632259607315,
0.06909553706645966,
-0.03441471979022026,
-0.030334625393152237,
0.008492807857692242,
0.016287121921777725,
0.0009063799516297877,
-0.002385137602686882,
0.012794648297131062,
-0.024946236982941628,
-0.024502748623490334,
... | 2025-01-05 | 190 | 39755633 | [
"T cell treatment",
"Breast cancer",
"breast cancer",
"cancer incidence",
"cancer",
"treatment efficacy",
"treatment resistance",
"Innovative treatment approaches",
"current clinical drugs",
"current clinical trials",
"therapeutic efficacy",
"chimeric antigen receptor",
"CAR-T cell therapy",... | [
"Breast cancer",
"CAR T cells",
"CAR signaling",
"In vivo studies",
"T cell exhaustion",
"T cell persistence"
] | 0 | 10.1186/s12935-024-03615-8 | [
"Marei",
"Bedair",
"Hasan",
"Al-Mansoori",
"Caratelli",
"Sconocchia",
"Gaiba",
"Cenciarelli"
] | [
"Department of Cytology and Histology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, 35116, Egypt. hanymarei@mans.edu.eg.",
"Department of Social Sciences, College of Arts and Sciences, Qatar University, P.O. Box 2713, Doha, Qatar.",
"Department of Mechanical and Industrial Engineering, College... | [
"39755633",
"38046195",
"33538338",
"11553815",
"17438091",
"21342044",
"32368385",
"35163586",
"17671126",
"8908700",
"36765623",
"32739874",
"33824268",
"30559421",
"37932456",
"35844304",
"20179677",
"31554797",
"37308954",
"38203786",
"32215875",
"29567707",
"30680780... | [] | 10.109007 | 4.202287 |
39754754 | 79 | CAR-T Cell Therapy: Pioneering Immunotherapy Paradigms in Cancer Treatment. | The world's one of the major causes of death are cancer. Cancer is still a complex disease over the years that needs to be cured. Traditional cytotoxic approaches, although they have been implemented for years for treating neoplastic diseases, yet are limited due to the intricacy and low efficiency of cancer cells. Res... | [
0.030936814844608307,
0.029974550008773804,
0.08674817532300949,
0.060767024755477905,
-0.01878822036087513,
-0.030335398390889168,
0.011426894925534725,
0.01326722651720047,
0.007938684895634651,
0.011499064974486828,
0.0068621509708464146,
-0.029565587639808655,
-0.03938068822026253,
0.0... | 2025-01-04 | 1 | 39754754 | [
"cancer cells",
"solid tumours",
"CAR-T cell treatment",
"CAR-T cell therapy",
"greater anti-tumour efficacy",
"CAR-T cells",
"innovative strategies",
"haematological malignancies",
"CAR-T cell technology",
"CAR-T cell activities",
"neoplastic diseases",
"clinical efficacy",
"Cancer",
"can... | [
"CAR-T cells",
"Cancer",
"T-lymphocytes",
"haematological malignancies.",
"immunotherapy"
] | 0 | 10.2174/0113892010330322241113062555 | [
"Borah",
"Hojaisa",
"Sarma",
"Mavi",
"Singh",
"Gulati",
"Goswami",
"Maru"
] | [
"Department of Zoology, Biswanath College, Biswanath Chariali, Assam -7841764, India.",
"Department of Zoology, Biswanath College, Biswanath Chariali, Assam -7841764, India.",
"Department of Zoology, Biswanath College, Biswanath Chariali, Assam -7841764, India.",
"Department of Botany & Life Sciences, Sri Aur... | [
"39754754"
] | [] | 9.840282 | 3.981104 |
39754193 | 80 | Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells. | Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a common, yet highly efficient, cellular immunotherapy for lymphoma. However, many recent studies have reported on its cardiovascular (CV) toxicity. This study analyzes the cardiotoxicity of CD19 CAR T cell therapy in the treatment of lymphoma for providing a ... | [
0.007283731829375029,
0.026916783303022385,
0.031228454783558846,
0.03474259003996849,
0.005741624161601067,
-0.01496623083949089,
-0.00694727199152112,
-0.0231783427298069,
0.02821277640759945,
0.0010015909792855382,
-0.03279859945178032,
-0.006274352315813303,
-0.05119173601269722,
0.029... | 2025-01-04 | 43 | 39754193 | [
"CV events",
"such CV events",
"CD19 CAR T cell therapy",
"CD19 CAR T cells",
"T cell therapy",
"adverse events",
"CV",
"non-randomized studies",
"many recent studies",
"associated adverse outcomes",
"Anti-CD19 chimeric antigen receptor",
"immune effector cell-associated neurotoxicity syndrome... | [
"CAR-T therapy",
"CD19",
"Cardiovascular toxicity",
"Chimeric antigen receptor T cells",
"Lymphoma"
] | 0 | 10.1186/s12967-024-06035-4 | [
"Liu",
"Yuan",
"Yang",
"Yang",
"Liu",
"Xu",
"Wang",
"He",
"Wang",
"Li"
] | [
"Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, No. 71 Bao Shan North Road, Yunyan District, Guiyang, 550001, Guizhou, China.",
"Department of Hematology Oncology, Affiliated Hospital of Guizhou Medical University, No. 4 Bei Jing Road, Yunyan... | [
"39754193",
"38614113",
"25113771",
"25863751",
"35653592",
"11807147",
"21047225",
"28064239",
"36097221",
"15030777",
"38693452",
"29385370",
"30501490",
"34516954",
"36138152",
"32888407",
"36087853",
"37890589",
"38267353",
"34359816",
"32305113",
"30621018",
"3393794... | [] | 6.178405 | 4.615945 |
39752754 | 81 | Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells. | Chimeric antigen receptor T (CAR-T) cells represent a promising approach for cancer immunotherapy, yet their efficacy is hindered by immunosuppressive signals in the tumor microenvironment. Casitas B-cell lymphoma protein b (Cbl-b) is a key negative regulator of T cell function. This study investigated whether inhibiti... | [
0.02338145673274994,
0.008275045081973076,
0.043175216764211655,
0.07661942392587662,
-0.02388520911335945,
-0.02997937798500061,
0.013847032561898232,
0.030593710020184517,
-0.002853569807484746,
-0.04538681358098984,
-0.004899293649941683,
0.005418404005467892,
-0.06138400360941887,
-0.0... | 2025-01-04 | 1 | 39752754 | [
"T cell function",
"CAR-T cell manufacturing efficiency",
"antitumor efficacy",
"CAR-T cell yield",
"human CAR-T cells",
"b",
"superior efficacy",
"anti-CD19 CAR-T cells",
"continuous NX-1607 treatment",
"CAR-T cell production",
"NX-1607",
"cytokine production",
"NX-1607-treated CAR-T cells"... | [
"CAR-T cells",
"Cancer immunotherapy",
"Cbl-b",
"NX-1607"
] | 0 | 10.1016/j.intimp.2024.113971 | [
"Wang",
"Li",
"Feng",
"Ma",
"Li",
"Zhao",
"Wu",
"Shi",
"Zong",
"Li",
"Cong",
"Wang"
] | [
"School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Anhui Medical University, Hefei, Anhui 230032, China.",
"School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui P... | [
"39752754"
] | [] | 7.52892 | 5.303981 |
39751840 | 82 | CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. | Chimeric antigen receptor (CAR) T cell therapy for solid tumors faces significant challenges, including inadequate infiltration, limited proliferation, diminished effector function of CAR T cells, and an immunosuppressive tumor microenvironment (TME). In this study, we utilized The Cancer Genome Atlas database to ident... | [
0.017982536926865578,
0.0088077737018466,
0.03513934463262558,
0.07592117041349411,
-0.02107902057468891,
-0.011531531810760498,
0.03683667629957199,
0.0001901254872791469,
-0.025735212489962578,
-0.008756165392696857,
-0.026721499860286713,
-0.01568884588778019,
-0.009031408466398716,
0.0... | 2025-01-03 | 43 | 39751840 | [
"CAR T cells",
"T cell infiltration",
"T cells",
"T cell therapy",
"solid tumors",
"various solid tumor types",
"tumor tissues",
"tumors",
"inadequate infiltration",
"CCR5",
"diminished effector function",
"key chemokines",
"CAR",
"limited proliferation",
"significant challenges",
"Chi... | [
"CAR T cells",
"CCR5",
"IL-12",
"Tumor Mircoenvironment"
] | 0 | 10.1007/s00262-024-03909-w | [
"Tian",
"Zhang",
"Ping",
"Zhang",
"Yao",
"Shen",
"Li",
"Wen",
"Zhang"
] | [
"Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.\nDepartment of Laboratory Medicine, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.",
"Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 45... | [
"39751840",
"37904019",
"34613616",
"37706523",
"38244129",
"37254607",
"34234299",
"31848460",
"31488817",
"36261831",
"28543380",
"37861969",
"33463538",
"38511468",
"35351469",
"33563975",
"27625360",
"30671927",
"26284335",
"33293583",
"32561858",
"27003285",
"2556348... | [] | 9.83024 | 5.137157 |
39750051 | 83 | [Anti-tumor therapy strategy of CAR-T cells based on stem cell memory and central memory cells]. | Cancer immunotherapy including immune checkpoint inhibitors and adoptive cell therapy has gained revolutionary success in the treatment of hematologic tumors; however, it only gains limited success in solid tumors. For example, chimeric antigen receptor T (CAR-T) cell therapy has shown significant effects and potential... | [
0.030005916953086853,
0.0048876493237912655,
0.027880851179361343,
0.05835428088903427,
-0.01640550047159195,
-0.029113389551639557,
0.0021981140598654747,
0.03051593154668808,
0.02006061188876629,
-0.013653541915118694,
-0.009127154015004635,
-0.021048767492175102,
-0.056101713329553604,
... | 2025-01-03 | 1 | 39750051 | [
"T cells",
"stem cell memory",
"adoptive cell therapy",
"better anti-tumor therapeutic effects",
"better anti-tumor effects",
"CAR-T cell therapy",
"tumor-specific T cells",
"stem cell memory and/or central memory",
"central memory phenotype",
"fully differentiated effector T cells",
"CAR-T cell... | [] | 0 | null | [
"Liu",
"Wang",
"Sun",
"Wang"
] | [
"Center for Cancer Immunotherapy, Institute of Biomedicine and Biotechnology, Chinese Academy of Sciences, Shenzhen 518055, China.",
"Center for Cancer Immunotherapy, Institute of Biomedicine and Biotechnology, Chinese Academy of Sciences, Shenzhen 518055; University of Chinese Academy of Sciences, Beijing 101408... | [
"39750051"
] | [] | 9.66513 | 4.894483 |
39748414 | 84 | Lentivirus-based production of human chimeric antigen receptor macrophages from peripheral blood. | Although chimeric antigen receptor (CAR) T cell therapy has shown remarkable efficacy against leukemic cells, it still has critical limitations. CAR macrophage has been regarded as a potential alternative to CAR T cells. However, due to the difficulties in gene transduction into macrophages, the production of primary h... | [
0.05070195719599724,
0.00017627747729420662,
0.026704559102654457,
0.043085191398859024,
-0.06194356456398964,
-0.028081083670258522,
0.021427884697914124,
0.014430556446313858,
0.02109522558748722,
-0.025373918935656548,
0.0024619698524475098,
0.009945383295416832,
-0.042465753853321075,
... | 2025-01-03 | 13 | 39748414 | [
"CAR T cells",
"CAR macrophage",
"CAR macrophages",
"functional CAR macrophages",
"primary human CAR macrophages",
"T cell therapy",
"peripheral blood mononuclear cells",
"leukemic cells",
"macrophages",
"target cancer cells",
"human PBMC",
"CAR",
"remarkable efficacy",
"PBMC",
"chimeric... | [
"CAR macrophages",
"Human PBMC",
"Lentivirus",
"Primary human macrophages"
] | 0 | 10.1186/s40364-024-00703-9 | [
"Choi",
"Kim",
"Lee",
"Park",
"Jeun",
"Lee",
"Park"
] | [
"Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.",
"Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.",
"Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, ... | [
"39748414",
"33312759",
"37680942",
"37321663",
"25035953",
"18451984",
"35921473",
"36978075",
"38012418",
"36638788",
"34510559",
"16397508",
"32361713"
] | [] | 10.312987 | 5.428725 |
39747430 | 85 | Antigen experience history directs distinct functional states of CD8 | Although chimeric antigen receptor (CAR) T cells are effective against B-lineage malignancies, post-CAR relapse is common, and efficacy in other tumors is limited. These challenges may be addressed through rational manipulations to control CAR T cell function. Here we examine the impact of cognate T cell antigen experi... | [
0.024174805730581284,
0.02044229581952095,
0.051068659871816635,
0.04301039129495621,
-0.02113441564142704,
-0.03673186153173447,
0.007013907190412283,
0.024298399686813354,
-0.029340997338294983,
0.011376743204891682,
0.007749286014586687,
-0.0020485552959144115,
-0.04466653987765312,
0.0... | 2025-01-03 | 72 | 39747430 | [
"cognate T cell antigen experience",
"CAR T cell function",
"post-CAR relapse",
"rational manipulations",
"other tumors",
"subsequent CD8",
"efficacy",
"CAR",
"B-lineage malignancies",
"the impact",
"These challenges",
"we"
] | [] | 0 | 10.1038/s41590-024-02034-1 | [
"DeGolier",
"Danis",
"D'Antonio",
"Cimons",
"Yarnell",
"Kedl",
"Kohler",
"Scott-Browne",
"Fry"
] | [
"Department of Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.\nDepartment of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.",
"Biostatistics and Bioinformatics Shared Resource, University of Colorado Cancer Center, University of Colorado Anschutz Medical... | [
"39747430",
"36813894",
"26369987",
"31554741",
"36255386",
"37046597",
"33644866",
"26205583",
"34971569",
"29155426",
"32193224",
"21903423",
"24493801",
"21653320",
"30209120",
"27460500",
"29167392",
"37516968",
"34433030",
"30194241",
"17555991",
"16025119",
"2882570... | [] | 8.060258 | 4.934047 |
39747173 | 86 | Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. | Suppression of chimeric antigen receptor-modified T (CAR-T) cells by the immunosuppressive tumor microenvironment remains a major barrier to their efficacy against solid tumors. To address this, we develop an anti-PD-L1-expressing nanovesicle loaded with the STING agonist cGAMP (aPD-L1 NVs@cGAMP) to remodel the tumor m... | [
0.0389421321451664,
-0.018263742327690125,
0.015967458486557007,
0.03534383326768875,
-0.0594666488468647,
-0.03771113604307175,
-0.025850947946310043,
0.009694105945527554,
0.007326802704483271,
-0.03697727248072624,
-0.007309047970920801,
0.0248093344271183,
-0.03354468196630478,
-0.0280... | 2025-01-03 | 83 | 39747173 | [
"immunosuppressive cell populations",
"STING agonists",
"Internalized STING agonists",
"solid tumors",
"tumor growth",
"CAR-T cell activity",
"CAR-T cell exhaustion",
"STING",
"CAR-T cells",
"CAR-T cell infiltration",
"poor cellular uptake",
"pulmonary delivery",
"myeloid-derived suppressor ... | [] | 0 | 10.1038/s41467-024-55751-4 | [
"Zhu",
"Xiao",
"Chen",
"Ding",
"Chen",
"Jiang",
"Huang"
] | [
"Center for Infection and Immunity, Guangdong Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China.",
"Center for Infection and Immunity, Guangdong Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital... | [
"39747173",
"35417527",
"36418477",
"36813894",
"37904019",
"33972771",
"38167707",
"37938576",
"31296767",
"37872225",
"34613775",
"33469002",
"35379957",
"35443752",
"37857711",
"34385695",
"30102295",
"38440217",
"38448658",
"37500747",
"37443252",
"33827917",
"3338240... | [] | 10.169621 | 3.755513 |
39746895 | 87 | Co-Expression of Dominant-Negative TGF-β Receptor 2 Enhances the Therapeutic Efficacy of Novel TREM1/DAP12-BB-Based CAR-T Cells in Solid Tumours. | Chimeric antigen receptor (CAR) T-cell therapy has exhibited remarkable efficacy in the treatment of haematological malignancies, yet its application in solid tumours is hindered by the immunosuppressive tumour microenvironment (TME). In this study, a novel SS1-TREM1/DAP12-BB CAR-T cell was devised to target ovarian ca... | [
0.05341605097055435,
0.01158243790268898,
0.050483789294958115,
0.05282960087060928,
-0.040856193751096725,
-0.00864406581968069,
0.040807321667671204,
-0.0003768415772356093,
-0.018595432862639427,
-0.0123399393633008,
-0.02178426831960678,
-0.0010889079421758652,
-0.03704425320029259,
0.... | 2025-01-03 | 1 | 39746895 | [
"CAR design",
"CAR",
"DNR co",
"CAR-T cell survival",
"DNR",
"CAR-T cell exhaustion",
"recurrent ovarian cancer",
"solid tumours",
"ovarian cancer",
"remarkable efficacy",
"tumour rechallenge",
"Chimeric antigen receptor",
"haematological malignancies",
"antitumor activity",
"-",
"expr... | [
"DAP12",
"chimeric antigen receptor (CAR) T‐cell",
"dominant‐negative TGF‐β receptor 2 (DNR)",
"ovarian cancer",
"tumour microenvironment (TME)"
] | 0 | 10.1111/imm.13888 | [
"Zhu",
"Hu",
"Lin",
"Wang",
"Wang"
] | [
"Nanjing CART Medical Technology Co. Ltd., Nanjing, P.R. China.",
"Nanjing CART Medical Technology Co. Ltd., Nanjing, P.R. China.",
"Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, P.R. China.",
"Nanjing CART Medical Technology Co. Ltd., Nanjing, P.R. ... | [
"39746895"
] | [] | 9.972128 | 5.861783 |
39743260 | 88 | [Fever Characteristics and Biomarker Changes of CRS in Patients with Relapsed/Refractory Multiple Myeloma after CAR-T Cell Therapy]. | To investigate the correlation of the clinical characteristics, fever characteristics, serum biomarkers with cytokine release syndrome (CRS) in patients with relapsed/refractory multiple myeloma (R/R MM) treated with chimeric antigen receptor T cell (CAR-T) immunotherapy.
104 R/R MM patients who received CAR-T cell the... | [
-0.0006119546014815569,
0.02669128030538559,
0.03867329657077789,
0.044552531093358994,
-0.024276994168758392,
0.008919447660446167,
0.013647425919771194,
-0.020051991567015648,
0.012876194901764393,
-0.007734659127891064,
-0.02926204726099968,
-0.03257051482796669,
-0.048553988337516785,
... | 2025-01-02 | 1 | 39743260 | [
"severe CRS",
"fever characteristics",
"CRS",
"chimeric antigen receptor T cell",
"serum biomarkers",
"Patients",
"patients",
"Xuzhou Medical University",
"cytokine release syndrome",
"104 R/R MM patients",
"fever",
"(R/R MM",
"a clinical characteristic",
"the clinical characteristics",
... | [
"chimeric antigen receptor T cells; multiple myeloma; cytokine release syndrome; fever"
] | 0 | 10.19746/j.cnki.issn.1009-2137.2024.06.017 | [
"Hua",
"Wang",
"Ji",
"Liu",
"Chen",
"Shao",
"Cheng",
"Cao"
] | [
"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.",
"Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.",
"Department of Hematology, The Affiliated Hospital of Xuzhou Medic... | [
"39743260"
] | [] | 5.3198 | 5.282726 |
39739533 | 89 | Protocol for production of tonic CAR T cells with dasatinib. | Chimeric antigen receptors (CARs) are synthetic molecules composed of an extracellular antigen-binding domain and an intracellular signaling domain, leading to tonic signaling and manufacturing challenges. We present a protocol for the expansion of tonic CARs by using a Food and Drug Administration (FDA)-approved kinas... | [
0.01995864138007164,
-0.0014919762033969164,
0.025594312697649002,
0.034355442970991135,
-0.0319436714053154,
0.011591270565986633,
-0.02591424062848091,
0.010514586232602596,
-0.036865655332803726,
-0.026111120358109474,
0.010016235522925854,
-0.02165672555565834,
-0.0376039519906044,
-0.... | 2025-01-01 | 1 | 39739533 | [
"tonic CARs",
"CAR quality",
"CARs",
"tonic",
"Chimeric antigen receptors",
"expansion",
"tonic CAR T cell proliferation",
"synthetic molecules",
"flow cytometry",
"quality",
"complete details",
"dasatinib",
"execution",
"T cell transduction",
"retrovirus",
"verification",
"an intrac... | [
"cancer",
"cell culture",
"health sciences",
"immunology"
] | 0 | 10.1016/j.xpro.2024.103529 | [
"Rosselle",
"Leray",
"Joaquina",
"Caulier",
"McCormack",
"Gelebart",
"Wälchli",
"Inderberg"
] | [
"Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway. Electronic address: lea.rosselle@rr-research.no.",
"Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway; Medical Faculty... | [
"39739533"
] | [] | 8.574634 | 4.567834 |
39737899 | 90 | PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. | Here we report results of a phase 1 multi-institutional, open-label, dose-escalation trial (NCT02744287) of BPX-601, an investigational autologous PSCA-directed GoCAR-T® cell product containing an inducible MyD88/CD40 ON-switch responsive to the activating dimerizer rimiducid, in patients with metastatic pancreatic (mP... | [
0.00678769638761878,
0.0034950627014040947,
0.049595098942518234,
0.07186228781938553,
-0.045040447264909744,
-0.025809694081544876,
0.011823116801679134,
0.03595644608139992,
0.05268213897943497,
-0.04612850025296211,
-0.002424403093755245,
-0.01648530922830105,
-0.03423579782247543,
0.00... | 2024-12-31 | 45 | 39737899 | [
"mCRPC patients",
"BPX-601 cell expansion",
"GoCAR-T® cell activation",
"patients",
"GoCAR-T® cells",
"chimeric antigen receptor-T cell activity",
"≥50% reduction",
"Rimiducid",
"rimiducid",
"mCRPC",
"circulating inflammatory cytokines",
"peripheral blood",
"Secondary objectives",
"Primary... | [] | 0 | 10.1038/s41467-024-53220-6 | [
"Stein",
"Dumbrava",
"Teply",
"Gergis",
"Guiterrez",
"Reshef",
"Subudhi",
"Jacquemont",
"Senesac",
"Bayle",
"Scripture",
"Chatwal",
"Bilen",
"Stadler",
"Becerra"
] | [
"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.",
"The University of Texas MD Anderson Cancer Center, Houston, TX, USA. eeileana@mdanderson.org.",
"University of Nebraska Medical Center, Omaha, NE, USA.",
"Thomas Jefferson University, Philadelphia, PA... | [
"39737899",
"36765623",
"36906275",
"36853475",
"33824268",
"21383499",
"9724721",
"28697888",
"28801306",
"30740516",
"9465086",
"10973799",
"12516096",
"22778595",
"16604582",
"20501618",
"22020316",
"22553195",
"24694017",
"38867077",
"10713670",
"31023743",
"11504275"... | [] | 5.729406 | 5.627012 |
39735543 | 91 | The approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of B cell malignancies has fueled the development of numerous
The CAR comprises a TROP2 specific single-chain variable fragment (scFv) fused to a truncated CD89 which requires association with the FcRγ signal adapter to trigger myeloid-... | [
0.01903236098587513,
-0.0033434443175792694,
0.020786870270967484,
0.015895158052444458,
-0.01846301555633545,
-0.0417131707072258,
-0.011415930464863777,
-0.007604810409247875,
-0.0009752922342158854,
-0.008871310390532017,
-0.011392692103981972,
-0.0034857802093029022,
-0.05428521707653999... | 2024-12-30 | 48 | 39735543 | [
"B cell malignancies",
"TROP2 CAR",
"myeloid cells",
"CAR expression",
"chimeric antigen receptor",
"flow cytometry",
"CAR",
"TROP2",
"functional activity",
"myeloid-specific cell activation",
"a TROP2 specific single-chain variable fragment",
"enzyme-linked immunosorbent assay",
"ELISA",
... | [
"RNA therapeutics",
"cancer therapy",
"cell therapy",
"lipid nanoparticles",
"myeloid cells"
] | 0 | 10.3389/fimmu.2024.1501365
10.1084/jem.20080421
10.1126/science.1178331
10.1084/jem.20141836
10.1038/nature10138
10.1038/s41573-022-00520-5
10.1097/00002371-200011000-00009
10.1007/bf01756597
10.1097/00002371-199507000-00003
10.1016/j.cell.2021.02.048
10.1126/scitranslmed.3006353
10.1038/gt.2012.61
10.4161/onci.28696
1... | [
"Argueta",
"Wang",
"Zhao",
"Diwanji",
"Gorgievski",
"Cochran",
"Grudzien-Nogalska",
"D'Alessandro",
"McCreedy",
"Prod'homme",
"Hofmeister",
"Ding",
"Getts"
] | [
"Myeloid Therapeutics, Inc., Cambridge, MA, United States.",
"Myeloid Therapeutics, Inc., Cambridge, MA, United States.",
"Myeloid Therapeutics, Inc., Cambridge, MA, United States.",
"Myeloid Therapeutics, Inc., Cambridge, MA, United States.",
"Myeloid Therapeutics, Inc., Cambridge, MA, United States.",
"... | [
"39735543",
"18779347",
"20133564",
"26056232",
"21654748",
"35974096",
"1701343",
"11186156",
"1651160",
"8535567",
"33765443",
"24382895",
"22895508",
"25097805",
"35157542",
"30188543",
"37165196",
"38246194",
"30995475",
"11123311",
"33536615",
"29296544",
"36460336",... | [] | 8.123181 | 4.755754 | |
39734708 | 92 | Severe refractory colitis after intraperitoneal infusion of CEA-directed CAR T cells in patients with colorectal cancer. | Chimeric antigen receptor T (CAR T) cells have shown their potential in hematological malignancies and the treatment of solid tumors, especially in metastases. However, CAR T-cell therapy may carry risks of inducing severe adverse effects, which are recognized as immune-related adverse events. Here, we report two cases... | [
0.037861596792936325,
0.05367965251207352,
0.073155477643013,
0.07354305684566498,
-0.0680200606584549,
-0.00015840008563827723,
0.014207182452082634,
-0.0030188746750354767,
0.004702419973909855,
0.008133096620440483,
-0.002697911113500595,
-0.04062309488654137,
-0.02732429839670658,
0.00... | 2024-12-30 | 12 | 39734708 | [
"CAR T cell therapy",
"CAR T therapy",
"anti-CEA CAR T therapy",
"novel cancer therapy",
"therapy",
"severe inflammation",
"colon cancer patients",
"severe adverse effects",
"Serious bowel inflammation",
"modified immune cells",
"serious side effects",
"severe colitis",
"CAR T",
"CAR T-cel... | [
"CAR-T-cell therapy",
"carcinoembryonic antigen",
"case report",
"colorectal cancer",
"immune-related adverse event"
] | 0 | 10.1177/17588359241309825 | [
"Ye",
"Yu",
"Shen"
] | [
"Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang Province, China.",
"Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang Province, China.",
"Department of Gastroenter... | [
"39734708",
"29567707",
"28366766",
"22750462",
"32843493",
"31155611",
"28529185",
"21157437",
"20400962",
"37999667",
"27080226",
"33252123"
] | [] | 6.289252 | 4.126767 |
39734655 | 93 | Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers. | Thyroid cancer treatment has recently been revolutionized by the introduction of specific targeted therapies (e.g. BRAF | [
-0.03578217700123787,
0.03906306251883507,
0.047941964119672775,
0.0630340427160263,
-0.021920427680015564,
0.026575187221169472,
-0.0005385909462347627,
0.022679133340716362,
-0.0024478493724018335,
0.031045395880937576,
0.00970424897968769,
-0.04544028639793396,
0.011503610759973526,
0.0... | 2024-12-30 | 71 | 39734655 | [
"specific targeted therapies",
"Thyroid cancer treatment",
"BRAF",
"the introduction",
"e.g. BRAF"
] | [] | 0 | 10.1016/j.coemr.2024.100544
10.1016/S2213-8587(22)00035-3
10.1038/nrendo.2016.110
10.1016/j.amjsurg.2009.11.008
10.1093/bjsopen/zrab099
10.1210/jc.2005-2838
10.1210/er.2019-00007
10.1530/ERC-15-0555
10.1016/S0140-6736(14)60421-9
10.1056/NEJMoa1406470
10.1200/JCO.2012.48.4659
10.1200/JCO.2011.35.5040
10.1016/j.ejca.2018... | [
"Prete",
"Nucera"
] | [
"Human thyroid cancers preclinical and translational research program, Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.",
"Human thyroid cancers preclinical and translational research program, Cancer Research Institute, Beth Israel Deaconess Medical Center,... | [
"39734655",
"35271818",
"27418023",
"20561605",
"34686878",
"16684830",
"31322645",
"27207700",
"24768112",
"25671254",
"24002501",
"22025146",
"30471649",
"35658604",
"35026411",
"29996921",
"33509020",
"35248904",
"33619218",
"29628290",
"33986723",
"20207826",
"3088285... | [] | 10.182327 | 4.483451 |
39723764 | 94 | Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers. | Despite recent advances in immunotherapy against B cell malignancies such as BCMA (B cell maturation antigen) and CD19-targeted treatments using soluble T cell-engaging (TCE) antibodies or chimeric antigen receptor T cells (CAR-T), there is still an important number of patients experiencing refractory/relapsed (R/R) di... | [
0.03525831550359726,
0.010779691860079765,
0.10155405104160309,
0.03409567475318909,
-0.0348033681511879,
0.009825569577515125,
-0.015177503228187561,
0.0504484549164772,
-0.028990168124437332,
-0.0004719274875242263,
0.0123088164255023,
-0.012409915216267109,
-0.025742359459400177,
0.0177... | 2024-12-26 | 1 | 39723764 | [
"B cell lymphoma",
"B cell malignancies",
"CD19 TCE",
"BCMA TCE",
"different strategies",
"(B cell maturation antigen",
"T cell-redirecting bispecific antibodies",
"dual-targeted STAb-T cells",
"single-targeted STAb-T cells",
"poor prognosis",
"poor response",
"BCMA",
"several clinical trial... | [
"Bispecific antibodies",
"STAb-T immunotherapy",
"T cell engagers",
"dual-targeting immunotherapy",
"haematological malignancies"
] | 0 | 10.1080/2162402X.2024.2444701 | [
"Velasco-Sidro",
"Arroyo-Ródenas",
"Díez-Alonso",
"Ramírez-Fernández",
"Álvarez-Vallina"
] | [
"Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario12 de Octubre, Madrid, Spain.\nImmuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain.\nH12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Rese... | [
"39723764"
] | [] | 5.273784 | 6.075217 |
39722028 | 95 | Current and future immunotherapy for breast cancer. | Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negative breast cancer, while ongoing clinical trials seek to e... | [
0.020130880177021027,
-0.04167334362864494,
0.031771183013916016,
0.08444224298000336,
-0.019277608022093773,
-0.00527764018625021,
0.023364882916212082,
0.03748072683811188,
0.01766587421298027,
0.01497964933514595,
0.007342346012592316,
-0.005282907281070948,
-0.026841172948479652,
0.003... | 2024-12-26 | 123 | 39722028 | [
"HER2 positive breast cancer",
"breast cancer",
"immune checkpoint inhibitors",
"T cell receptor engineered cells",
"recent major clinical trials",
"ongoing clinical trials",
"tumor infiltrating lymphocytes",
"hormone receptor",
"Antibody drug conjugates",
"FDA approval",
"bispecific antibodies"... | [
"Antibody drug conjugate",
"Bispecific antibody",
"Breast cancer",
"Cellular therapy",
"Immune checkpoint inhibitor",
"Immunotherapy"
] | 0 | 10.1186/s13045-024-01649-z | [
"Heater",
"Warrior",
"Lu"
] | [
"Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, 60611, USA.",
"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N St. Clair, Suite 850, Chicago, IL, 60611, USA.",
"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N St. ... | [
"39722028",
"35685630",
"32266087",
"29567705",
"37939105",
"37970594",
"27166974",
"31079793",
"22068656",
"35303904",
"30345906",
"35053471",
"33223991",
"35857659",
"19917869",
"31901781",
"32461104",
"37129893",
"35680043",
"29428479",
"31095287",
"35017545",
"3224612... | [] | 10.752193 | 4.30269 |
39717765 | 96 | Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma. | This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose lymphoma had not res... | [
0.003224636660888791,
0.022101305425167084,
0.025943946093320847,
0.040090739727020264,
-0.02973763644695282,
-0.03867116570472717,
0.0030548383947461843,
0.043027788400650024,
-0.006027072202414274,
-0.014085604809224606,
-0.0016337343258783221,
0.0005736426683142781,
-0.06520251929759979,
... | 2024-12-24 | 26 | 39717765 | [
"T cell therapy",
"autologous hematopoietic stem cell transplantation",
"refractory BL",
"tandem anti-CD19/CD22 CAR T cell therapy",
"myeloablative ASCT",
"BL",
"sustained complete remission",
"multiple chemoimmunotherapy regimens",
"tandem anti-CD19/CD22 chimeric antigen receptor",
"signaling dom... | [
"CAR T-cell therapy",
"CD19/CD22 dual target",
"autologous hematopoietic stem cell transplantation",
"immunotherapy",
"relapsed/refractory Burkitt lymphoma"
] | 0 | 10.3389/fimmu.2024.1497736
10.1002/ajh.24720
10.1080/10428194.2022.2133542
10.1056/NEJMoa1707447
10.1056/NEJMoa1804980
10.1038/nm.4441
10.1200/JCO.19.03279
10.1080/14712598.2022.2086043
10.1182/blood.2022018598
10.1007/s00432-020-03198-7
10.1182/bloodadvances.2021004557
10.1038/leu.2017.249
10.1186/s13045-018-0572-x
10... | [
"Luo",
"Chen",
"Qin",
"Weinkove",
"Zhao",
"Ye",
"Chen",
"Tang",
"Liu",
"Huang",
"Shi",
"Yuan",
"Tan",
"Qin",
"Tang",
"Li",
"Zheng"
] | [
"The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.",
"The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.",
"China-New Zealand Joint Laboratory on Biomedicine and Health, Key Laboratory of Immune Response and Immunotherapy, Guangdong Provincial Key Laborat... | [
"39717765",
"28295472",
"36260003",
"29226797",
"30501490",
"29155426",
"32286905",
"35653589",
"36821767",
"32222815",
"34521107",
"28841215",
"29458388",
"32514352",
"23200705",
"38510818",
"33596362",
"36399695",
"34097852",
"38730674",
"38564164",
"34496014",
"3462805... | [] | 6.496071 | 5.791145 |
39717204 | 97 | A GD (Gamma-Delta) type of cancel culture. | γδ T cells represent an 'unconventional' class of CD3+ lymphocytes with unique phenotypical and functional attributes that distinguishes them from their αβ T-cell receptor-expressing counterparts. Studies investigating the roles of γδ T cells in cancer have shown that these cells are indispensable for effective tumor c... | [
0.010538208298385143,
0.04704814404249191,
0.03322609141469002,
0.04540899023413658,
-0.008190231397747993,
-0.007691839709877968,
0.02207319810986519,
0.043947041034698486,
0.014442273415625095,
0.030501550063490868,
-0.014209691435098648,
0.006013922393321991,
0.02531827986240387,
0.0085... | 2024-12-24 | 87 | 39717204 | [
"γδ T cells",
"cancer treatment",
"γδ chimeric antigen receptor T therapy",
"cancer therapeutics",
"cancer",
"effective tumor control",
"γδ T-cell-based treatment",
"γδ T-cell-based strategies",
"research efforts",
"strategies",
"Several therapeutic approaches",
"proper functioning",
"therap... | [
"T-cell product manufacturing/scalability",
"T-cell therapy for patients with solid tumors",
"tumor-infiltrating lymphocytes (TIL)"
] | 0 | 10.1016/j.iotech.2024.100740 | [
"Lim",
"Iyer"
] | [
"Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.\nCancer Therapeutics Research Laboratory, National Cancer Centre, Singapore.",
"Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.\nCancer Therapeutics Research Laboratory, National Cancer Centre, Singapore... | [
"39717204",
"37933232",
"37654012",
"36851283",
"37327346",
"36624304",
"29707004",
"37345160",
"37368791",
"33526858",
"37063836",
"32939032",
"37820582",
"31285310",
"37989744",
"31611377",
"28270598",
"26755823",
"24076636",
"28783722",
"29025772",
"38594286",
"3529609... | [] | 10.242367 | 4.348849 |
39715901 | 98 | Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors. | Resistance to chimaeric antigen receptor (CAR) T cell therapy develops through multiple mechanisms, most notably antigen loss and tumour-induced immune suppression. It has been suggested that T cells expressing multiple CARs may overcome the resistance of tumours and that T cells expressing receptors that switch inhibi... | [
0.02374090813100338,
0.008248014375567436,
0.05553168058395386,
0.029474887996912003,
-0.047580890357494354,
-0.03106009215116501,
-0.003966106101870537,
0.01810600236058235,
-0.012743554078042507,
-0.028013527393341064,
0.006201491691172123,
-0.006538966670632362,
-0.025053653866052628,
0... | 2024-12-24 | 111 | 39715901 | [
"T cells",
"CAR T cell resistance",
"T cell therapy",
"cells",
"leukaemia cells",
"multiple switch receptors",
"multiple CARs",
"multiple mechanisms",
"multiple inhibitory ligands",
"multiple features",
"a single T cell product",
"Zip-sorted multi-CAR multi-switch-receptor T cells",
"antigen... | [] | 0 | 10.1038/s41551-024-01287-3
10.1056/NEJMra1706169
10.1038/s41571-020-0427-6
10.1016/j.coi.2021.02.010
10.1158/2159-8290.CD-18-0442
10.1038/s41586-023-05707-3
10.1016/j.coi.2018.03.002
10.1158/1078-0432.CCR-19-1835
10.1016/j.ccell.2017.09.004
10.1038/s41586-019-1054-1
10.1172/JCI87366
10.1158/2326-6066.CIR-15-0231
10.115... | [
"James",
"Chen",
"Ng",
"Fischman",
"Jahn",
"Boardman",
"Rajagopalan",
"Elias",
"Massa",
"Manuele",
"Nichols",
"Lazrak",
"Lee",
"Roche",
"McFarland",
"Petrichenko",
"Everett",
"Bushman",
"Fei",
"Kousa",
"Lemarquis",
"DeWolf",
"Peled",
"Vardhana",
"Klebanoff",
"van de... | [
"Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. scjames@coh.org.\nWeill Cornell Medical College, New York, NY, USA. scjames@coh.org.\nDepartment of Immunology, Sloan Kettering Institute, New York, NY, USA. scjames@coh.org.\nCenter for Ce... | [
"39715901",
"29972754",
"32978608",
"33752101",
"30135176",
"36813894",
"29554494",
"32015021",
"29017060",
"30918399",
"27571406",
"27059623",
"36416874",
"34312556",
"29419431",
"34642489",
"37863088",
"30814732",
"31152140",
"35554512",
"30181329",
"27454297",
"2904236... | [] | 8.66751 | 4.793289 |
39713739 | 99 | Titrating chimeric antigen receptors on CAR T cells enabled by a microfluidic-based dosage-controlled intracellular mRNA delivery platform. | Chimeric antigen receptor (CAR) T-cell therapy shows unprecedented efficacy for cancer treatment, particularly in treating patients with various blood cancers, most notably B-cell acute lymphoblastic leukemia. In recent years, CAR T-cell therapies have been investigated for treating other hematologic malignancies and s... | [
0.025999438017606735,
0.00597760546952486,
0.04152862727642059,
0.07163058966398239,
-0.05612656846642494,
-0.010967332869768143,
0.0236335638910532,
0.0003195266181137413,
-0.01673729531466961,
0.011099469847977161,
-0.00901674572378397,
-0.03128489851951599,
-0.060052912682294846,
0.0135... | 2024-12-23 | 45 | 39713739 | [
"CAR T cells",
"primary T cells",
"CAR surface density",
"pro-inflammatory cytokine release",
"CAR T-cell therapies",
"CAR T-cell therapy",
"cytokine release syndrome",
"CAR expression density",
"various blood cancers",
"CAR gene",
"other hematologic malignancies",
"cancer treatment",
"CAR) ... | [] | 0 | 10.1063/5.0231595
10.1056/NEJMoa1709919
10.1056/NEJMoa1709866
10.1038/nrd.2017.266
10.1056/NEJMoa1707447
10.1001/jama.2020.15848
10.1093/jnci/djac088
10.1038/mto.2016.11
10.1016/j.omtm.2021.03.007
10.1126/sciadv.abo0514
10.1038/mto.2016.15
10.1172/JCI35700
10.3390/diseases6020042
10.1038/nature21405
10.1111/imr.12137
1... | [
"Chen",
"Mirza",
"Jiang",
"Lee"
] | [
"Department of Biomedical Engineering, University of California, Irvine, California 92697, USA.",
"Department of Biomedical Engineering, University of California, Irvine, California 92697, USA.",
"Department of Biomedical Engineering, University of California, Irvine, California 92697, USA.",
null
] | [
"39713739",
"29385376",
"29385370",
"29375140",
"29226797",
"32870282",
"35438170",
"27626062",
"33869653",
"36179026",
"27347557",
"18688285",
"29883422",
"28225754",
"24329797",
"11159443",
"33855089",
"30381459",
"30923112",
"33093518",
"30824814",
"30288138",
"3038999... | [] | 6.512552 | 4.31325 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.